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PREFACE
The studies described in this thesis were carried out in conjunction 
with clinical trials of antihypertensive agents conducted under the 
auspices of the Glasgow Blood Pressure Clinics and the M.R.C. Blood 
Pressure Unit, Western Infirmary, Glasgow. The data resulting from 
investigations of blood pressure and related aspects have formed the 
basis for papers published in the journals Hypertension, the British 
Journal of Clinical Pharmacology and the American Journal of Medicine.
The physical investigations reported in this thesis were carried out by 
medical and nursing staff of the respective blood pressure clinics. The 
psychological investigations were organised, scored and collated by the 
author of the thesis. In more than ninety percent of patients the tests 
were administered by him. In exceptional situations in which patients 
would otherwise have been lost to the study the tests were administered 
by a research assistant who had been trained in their use by the author.
Training in the administration of the Standardised Psychiatric Interview 
was provided by the General Practice Research Unit, Institute of 
Psychiatry, London. Professor Neil Brookes of the Department of 
Psychological Medicine, University of Glasgow provided training and 
supervision in the use of the Wechsler Memory Scale and the Digit Symbol 
Substitution Test.
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SUMMARY
This thesis describes three studies of the effects of anti-hypertensive 
drugs on various aspects of psychological well-being.
The first investigation was a small pilot study of the effects of 
captopril on psychiatric status. This was prompted by anecdotal reports 
of mood elevation in hypertensive patients receiving this drug. No 
evidence for a euphoriant effect of captopril was found. Patients on 
captopril had significantly higher scores on a questionnaire of 
psychiatric symptoms.
The second and third trials were investigations of the effects of anti­
hypertensive agents on aspects of "quality of life". In all, four drugs 
were assessed for effects on psychiatric well-being, social adjustment 
and intellectual functioning. Patients on atenolol performed less well 
on tests of concentration and information processing, compared to those 
on enalapril. Patients on nicardipine and propranolol had impairment of 
performance on tests of non-verbal memory. There was no demonstrable 
decrement in psychiatric well-being and social functioning in patients 
on any of the drugs.
x
INTRODUCTION
In adult populations living in developed societies there is a continuous 
distribution of levels of systolic and diastolic blood pressures. Apart 
from patients in whom hypertension is secondary to other disease, there 
is no point of discontinuity at which normal blood pressure can be said 
to end and high blood pressure to begin (Pickering, 1961). In people 
with blood pressures at the upper end of the distribution, there is an 
increased risk of various adverse cardiac, vascular and other events 
such as stroke, coronary heart disease, cardiac failure and progressive 
renal impairment.
The first controlled trial which demonstrated that antihypertensive drug 
therapy could prevent the development of complications of raised blood 
pressure was that of Hamilton et al (1964). This trial revealed a 
protective effect, particularly with regard to stroke, in adults with 
phase IV diastolic blood pressures of llOmmHg or above, who were free of 
overt cardiovascular disease at the beginning of the trial.
Large controlled trials carried out in more recent times have examined 
the issue of whether drug treatment of mild hypertension is of benefit 
in the prevention of hypertension-related morbidity.
Among the first of these were the studies carried out in the U.S.A. 
under the auspices of the Veterans* Administration. Two trials were 
carried out which examined the effects of treatment in men with phase V 
diastolic pressures between 90 and 114mmHg and in those with phase V 
diastolic pressures between 115 and 129 mmHg (Veterans Administration
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Cooperative Study Group, 1967; 1970). The trials were randomised, 
double-blind and placebo-controlled and treatment consisted of 
hydrochlorothiazide and, where indicated, reserpine and hydralazine. 
Overall mortality was reduced when the two groups were considered in 
combination. There were fewer cardiac events and fewer strokes in 
treated patients but, in tbe case of strokes, the numbers were too small 
to reach statistical significance. There are, however, some problems in 
the analysis of the data of this trial. Approximately sixty percent of 
the patients had evidence of cardiovascular disease at the outset of the 
trial. The results of the trial were apparently inspected continually by 
the review committee and the trial was not terminated according to 
predetermined criteria (Robertson, 1987).
A large Australian study recruited 3427 men with phase V diastolic blood 
pressures of 95mHg or above. Subjects were randomly allocated to active 
treatment or to placebo and followed up for four years. The actively 
treated group showed a reduced mortality mainly accounted for by a two- 
thirds reduction in deaths from cardiovascular disease (myocardial 
infarction, stroke and aortic aneurysm). In addition, they experienced 
fewer non-fatal cerebro-vascular accidents. There was, however, little 
difference in the incidence of ischaemic heart disease (Australian 
National Blood Pressure Study Management Committee, 1980).
The Hypertension Detection and Follow-up Program (HDFP), mounted in the 
United States, recruited patients by population screening. Comparisons 
were made between patients allocated to "stepped care" with those 
allocated to "referred care" (Hypertension Detection and Follow -up 
Program Cooperative Group, 1982). Over seventy percent of patients in
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each group were classified as having mild hypertension on the basis of 
having diastolic pressures between 90 and 104 mmHg. "Stepped care" 
consisted of antihypertensive drug treatment according to a set protocol 
along with advice on reduction of intake of alcohol, salt and 
cholesterol and counselling on smoking. The "referred care" group were 
returned to their usual medical practitioner for whatever care he 
considered to be appropriate. The "stepped care" group had fewer strokes 
and myocardial infarctions; the decrease in myocardial infarctions was 
also found in those whose diastolic pressure at entry was between 90 and 
104 mmHg. This trial has been used to justify prophylactic treatment in 
those with diastolic pressures persistently equal to or greater than 90 
mmHg (Moser and Gifford, 1985), although the advantages found may have 
been achieved by interventions other than antihypertensive therapy.
An earlier study of similar design was carried out in Gothenburg 
(Berglund et al, 1978). Men with hypertension were treated either at a 
special hospital clinic for the treatment of hypertension or by their 
usual medical practioner. Those attending the hypertension clinic did 
better and suffered fewer fatal and non-fatal myocardial infarctions. 
This group also experienced fewer deaths from non-cardiovascular 
diseases. The authors suggest that more effective control of high blood 
pressure and in particular greater use of beta-blockers for the 
treatment of hypertension may lead to reduced morbidity and mortality.
It may of course be the case that the greater attention and supervision 
available at the clinic contributed to the favourable outcome in those 
attending.
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A study carried out in Oslo by Helgeland et al (1980) assessed treatment 
of men aged 40-49 with blood pressures in the range 150-179 mm Hg 
systolic and/or 90-109 mm Hg phase V diastolic. Patients were randomly 
allocated to treatment with hydrochlorothiazide and methyldopa or 
propranolol or to placebo. At five-and-half year follow-up there was no 
difference in the number of deaths or cardiovascular events. Coronary 
events were more common in the treated group although this was not 
statistically significant. At ten year follow-up there had been a 
significantly greater number of deaths in the treated group (Leren and 
Helgeland ,1986). The authors suggested that this raised the possibility 
that the potential adverse cardiac effects of thiazide diuretics, such 
as hypokalaemia, may outweigh the benefits of lowered blood pressure.
The large trials published prior to the inception of the studies 
reported here suggested that there was benefit from antihypertensive 
therapy in patients with phase V diastolic pressures persistently above 
95 mm Hg. Numerically the advantages of treatment were modest especially 
in the lower range of pressures and uncertain in those with diastolic 
pressures in the range 90-95 mmHg (Robertson, 1987).
As more trials have been completed there has been a tendency for the 
recommended threshold at which antihypertensive treatment should be 
instituted to become progressively lower (Noser et al, 1986). It 
was estimated in 1984 that there were thirty-five million people in the 
United States, and equivalent numbers in other developed countries, with 
blood pressures which would qualify them for treatment (Subcommittee on 
Definition and Prevalence, 1985). In a situation in which very large 
numbers of people may be subjected to long-term drug treatment, it
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becomes of the utmost importance to scrutinise these treatments very 
closely for possible adverse effects on well-being in the psychological, 
as well as the physical, sphere.
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PSYCHIATRIC SIDE-EFFECTS OF ANTI-HYPERTENSIVE MEDICATION
The effects of anti-hypertensive drugs on mental well-being have been 
studied since the earliest days of the treatment of hypertension with 
Rauwolfia alkaloids and the pure derivative of these, reserpine. As new 
drugs have been developed, case reports and systematic studies relating 
to psychiatric effects have appeared. The psychiatric side-effects of 
Rauwolfia and reserpine will be discussed in view of their historical 
importance. The main groups of commonly-used anti-hypertensive agents 
will then be considered in turn.
RESERPINE AND THE RAUWOLFIA ALKALOIDS
The Rauwolfia alkaloids were introduced into Western medicine in the 
early 1950s for the treatment of hypertension and various psychiatric 
disorders. In patients with hypertension, psychiatric side-effects were 
soon recognised as an important adverse conseqence of treatment.
These agents may have both central and peripheral actions. Reserpine 
lowers the brain content of noradrenaline, 5-hydroxytryptamine and 
adenosine triphosphate and has a relaxant effect on vascular smooth 
muscle. Arteriolar tissue and the sympathetic nervous system are 
depleted of noradrenaline (Laurence and Bennett, 1987).
Among the first reports of psychiatric side-effects was that of Fries 
(1954) who described five patients who became depressed while taking 
reserpine. Other symptoms which they experienced included lethargy,
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poor concentration and fatiguability. One patient was troubled with 
drowsiness; another developed insomnia with early wakening. Symptoms had 
their onset at least two months after treatment was commenced. 
Improvement in symptoms occurred between one week and two months after 
withdrawal of medication. One patient with a past history of psychiatric 
disorder required electro-convulsive therapy (ECT). Doyle and Smirk 
(1954) reported that fatigue, drowsiness, depression and mental 
excitement were prominent in patients taking reserpine. Schroeder and 
Perry (1955) gave histories of five patients on reserpine who became 
depressed. Agitation, paranoia and suicidal tendencies were prominent 
in this group. Recovery occurred over a period of several weeks. Two 
patients were treated with ECT. Achor et al (1955) found symptoms of 
depression in ten out of fifty-eight patients on treatment with 
Rauwolfia. Three were of sufficient severity to require referral to a 
psychiatrist, three were "moderately depressed" and four had "mild but 
definite" depression. Muller et al (1955) described psychiatric symptoms 
in seven patients out of a group of ninety-three being treated with 
Rauwolfia. The most common symptoms were insomnia (present in seven 
patients), fatigue and lassitude (six), poor concentration (five), 
anxiety and apprehension (five), crying episodes (four) and drowsiness 
(four). Onset of symptoms was between three and six months after 
initiation of treatment. Patients were on higher than average doses of 
medication. Five out of seven were treated with ECT. Kass and Brown 
(1958) reported depression in four patients on either Rauwolfia or 
reserpine. In one patient there was clinical and EEG evidence of an 
acute organic brain reaction; this cleared within three weeks of drug 
withdrawal. Lemieux et al (1956) found symptoms of depression, lack of
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energy, loss of interest, insomnia and anorexia in thirty out of 195 
patients on reserpine or Rauwolfia. Ten of these patients required 
psychiatric hospitalisation. On average four and a half months elapsed 
between commencement of treatment and the onset of symptoms. Reduction 
of dosage or withdrawal of treatment led to improvement in most cases.
Quetsch et al (1959) compared the incidence of depression in patients 
being treated with Rauwolfia, alone or in combination with other drugs, 
with hypertensive patients on no specific therapy. Depression was found 
in 28% of patients on Rauwolfia alone, 21% of those on combination 
therapy but in only 5% of patients on no treatment. The average time to 
onset of depression was five months. Recovery was gradual over a period 
of weeks after withdrawal of medication. Nineteen patients had a past 
history of depression; of these eleven became depressed on Rauwolfia, 
none to a severe degree.
In summary, Rauwolfia and its derivative reserpine, cause psychiatric 
morbidity which appears on average between four and five months after 
starting on treatment. The most prominent symptom is depression of mood. 
A wide variety of accompanying symptoms is described, with fatigue and 
lassitude, drowsiness, insomnia and anxiety among the most common. It is 
possible that those with a past history of depression are more 
vulnerable to pychiatric morbidity. Symptoms cleared in most patients 
within weeks of drug withdrawal. Many patients, however, required 
hospitalisation and specific treatment such as ECT.
These early papers were published before the days of the widespread use 
of standardised psychiatric nomenclatures and no attempt is made in any
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of them to come to specific diagnoses. Ratings of severity are either 
subjective or based on some simple criterion such as requirement for 
hospital care. It thus difficult to compare the syndromes described with 
psychiatric morbidity as found in other settings. Despite these 
problems, reserpine-induced depression has been an influential model for 
the "catecholamine hypothesis of affective disorders" which explains 
depressive illness in terms of a functional depletion of central 
catecholamines (Schildkraut,1965).
ALPHA-METHYLDOPA
Methyldopa is one of the few drugs which have passed from the design 
stage in the laboratory to clinical application (Sourkes, 1965). Despite 
this, the exact mode of action of this drug remains unclear (Laverty, 
1973). One action is inhibition of dopamine decarboxylase and it was 
initially thought that the anti-hypertensive effect was peripheral and a 
result of reduced catecholamine synthesis. The drug warn then shown to be 
metabolised to alpha-methylnoradrenaline and alpha-methyldopamine. It 
was thought that these substances acted as "false transmitters" which 
replaced noradrenaline at sympathetic synapses thus producing 
significant blockade in the sympathetic nervous system (Laurence and 
Bennett, 1987).
Central nervous system actions are now thought to be the most important 
in producing the hypotensive effect. Depletion of noradrenaline and 
serotonin in the central nervous system have been demonstrated
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(Smith,1960). A centrally-mediated hypotensive effect has been 
demonstrated in animal studies (Henning and van Zwieten,1968; Ingenito 
et al,1970). Destruction of central adrenergic neurones in rats and cats 
reduces the hypotensive action of methyldopa.
Sedation is the most common central side-effect and has been reported in 
nearly every study (Paykel et al,1982). This complaint is usually 
transient, appearing with the initial dose and passing off within two 
weeks. Bulpitt and Dollery (1973) found that 56% of patients on 
methyldopa complained of sleepiness. Those complaining of this symptom 
were, on average, on a significantly higher dose of medication. Patients 
on methyldopa slept for more hours in a day. In a series described by 
Prichard et al (1968), 83% of patients on methyldopa complained of 
tiredness.
Sleep disturbance and insomnia have also been widely reported (Amery et 
al,1972; Irvine et al,1962). This symptom has sometimes necessitated 
withdrawal of treatment (Tuomilehto et al, 1974).
The issue of depression in methyldopa treatment has been of interest in 
view of its action in depleting the central nervous system of serotonin 
and catecholamines. Depression has been widely reported in the 
literature. Hamilton and Kopelman (1963) found depression in three out 
of sixty-nine patients on methyldopa. In two of these, both previously 
treated for depression, this necessitated withdrawal of medication. 
Prichard et al (1968) found "mild depression" in four out of thirty 
patients on methyldopa. Dubach (1963) described one patient who 
developed symptoms of depression, auditory and visual hallucinations and
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psychomotor retardation. These features cleared within forty-eight hours 
of drug withdrawal. Mielczarek (1962) reported on a patient who became 
depressed and agitated after five days on methyldopa. His symptoms 
failed to improve and he was treated with ECT ten weeks later. Fullerton 
and Morton-Jenkins (1963) described a thirty-four year old woman who 
became acutely psychotic two days post-partum after seven days on 
medication. Symptoms cleared approximately one week after drug 
discontinuation. A case report of methyldopa-induced depression by 
McKinney and Kane (1967) described a depressive illness occurring in a 
patient who had previously suffered from depression while on reserpine. 
Gillespie et al (1962) described two patients, both with a past history 
of depression who became depressed shortly after commencing on 
methyldopa. In both patients depression cleared on withdrawal of 
medication. Raftos et al (1964) described seven patients in whom the 
development of depression necessitated withdrawal of methyldopa with 
subsequent rapid improvement. Six of these patients were considered to 
have a significant past psychiatric history. Igloe (1964) found no 
depression in a series of fifty-one patients on methyldopa.
Again, diagnoses of depression are made in these reports without 
reference to standard diagnostic procedures. It is always impossible to 
be certain that the depression was produced by medication rather than 
being a coincidental occurence. Three studies will be described which 
assessed the incidence of depression in methyldopa-treated patients, 
using standardised rating scales.
Snaith and McCoubrie (1974) investigated the incidence of depression in
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a group of hypertensive patients drawn from a general practice 
population. Depression was assessed using the Wakefield Self Assessment 
of Depression Inventory, which had been validated by the authors. Two 
hundred and sixty-four hypertensive patients, including eighty-seven on 
methyldopa alone and forty-seven on methyldopa in combination with other 
drugs completed the assessment and were compared with fifty-six control 
patients. In patients on methyldopa, scores on the inventory did not 
differ significantly from controls. Depression is said to be commoner in 
the early in treatment with methyldopa. Patients in this study had 
however typically been on treatment for some years and it is possible 
that depression was a feature of the earlier stages of treatment.
DeMuth and Ackermann (1983) compared the incidence of depression in 
patients on methyldopa with that in a group of hypertensive patients on 
other medication. Severity of depression was assessed using the Beck 
Depression Inventory. The incidence of significant depression was 26% in 
those on methyldopa and 32% in those on other unspecified medication.
The conclusion drawn from this study was that methyldopa was no more 
likely to cause depression than other anti-hypertensive agents.
Bant (1978) studied the incidence of depression over a year in a group 
of eighty-nine new referrals to a hypertension clinic and in forty-six 
non-hypertensive medical out-patients. Depression was assessed with a 
rating scale whose validation is described by the author. There was no 
excess of depression in the hypertensive group as a whole. The incidence 
of depression in patients on methyldopa was no higher than in those on 
other drugs.
12
Depression seems therefore to be no more common in patients on 
methyldopa than in those in various comparison groups. These comparison 
groups have not always been precisely described in terms of factors 
which may predispose their members to a higher than average rates of 
depression. Case reports which describe relief of depression shortly 
after withdrawal of the drug suggest a role for methyldopa in causing 
depression. In many patients suffering this side-effect there was a past 
history of depression suggesting the existence of pharmacological 
vulnerability perhaps mediated by cerebral amine depletion.
Disturbance of sexual functioning is a peripheral side-effect of 
methyldopa which could lead to psychiatric morbidity in the form of 
marital dysharmony and reactive depression. Bulpitt and Dollery (1973) 
found impotence in 36% and failure of ejaculation in 18.5% of men on a 
combination of methyldopa and diuretic. Alexander and Evans (1975) found 
failure of erection in 53% of methyldopa-treated men and for this reason 
felt that it should not be used as a first-line treatment for 
hypertension.
BETA-BLOCKERS
The precise mode of antihypertensive action of beta-blocking drugs 
remains a subject of some controversy (Laurence and Bennett, 1987). One 
suggestion has been that the fall in blood pressure is due to the 
decreased heart rate and cardiac output which follow acute 
administration of these drugs. A compensatory increase in peripheral
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resistance occurs which declines with continued administration . It is 
clear however from the time course of these changes that they have 
little influence in lowering blood pressure. Further research has 
demonstrated that beta-blockers suppress release of renin from the 
kidney, thus producing lower circulating levels of the pressor peptide 
angiotensin-II. In the case of propranolol, a relationship between lower 
plasma renin levels and decreased blood pressure seems to occur only at 
low doses. A central effect, mediated by reduced sympathetic outflow, 
has been suggested. Against this notion is the fact that beta-blockers 
vary in the degree to which they penetrate the brain and despite this 
all reduce blood pressure to a similar degree. A final possibility is 
that beta-blockers act presynaptically to prevent neurotransmitter 
release. Administered adrenaline has been shown to have an important 
pressor effect (Tung et al, 1981). This is thought to be mediated by 
stimulation of presynaptic beta-receptors which promote release of 
transmitter into the synaptic cleft. Suppression of the pressor effect 
of exogenous adrenaline has been achieved using the beta-blocker 
metoprolol (Rand et al, 1983).
Beta-blockers show some variability in their pharmacodynamic and 
pharmacokinetic characteristics. An important pharmacokinetic variable 
in the present context is the degree to which a drug is lipophilic or 
hydrophilic. Lipophilicity is high in propranolol, intermediate in 
oxprenolol and others and low in atenolol and sotalol. With regard to 
pharmacodynamics, some beta-blockers show partial agonist activity. This 
is not a feature of atenolol or propranolol, the two beta-blockers which 
are examined in the present research. Labetalol possesses alpha- 
adrenergic blocking activity in addition to being a beta-blocker.
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The degree to which beta-blockers penetrate the brain depends on factors 
such as ionization, protein binding and lipophilicity. Drugs which are 
highly lipid-soluble appear in the brain in higher concentrations (Patel 
and Turner,1981). Early studies on animals demonstrated the presence of 
central effects of lipophilic beta-blockers such as propranolol 
(Leszkovszky and Tardos, 1965). Day and Hemsworth (1977) demonstrated a 
high uptake into the rat brain of propranolol (blood/brain ratio 8.37) 
in comparison to the hydrophilic drug, atenolol where the blood/brain 
ratio was only 0.054. Pretreatment with atenolol however led to an 
increase in central nervous system (CNS) uptake of this drug. Garvey and 
Ram (1975) demonstrated that CNS levels in the rat brain of propranolol 
and pindolol were higher for a given dose than those of the more 
hydrophilic sotalol. The presence of central beta-adrenergic receptors 
was demonstrated in the mouse by Atlas et al (1977) and in the rat by 
Maguire et al (1976). Middlemiss et al showed that propranolol has an 
affinity for 5-hydroxytryptamine (5-HT) receptors in the rat brain.
Green and Grahame-Smith (1977) showed that (-)propranolol inhibits the 
behavioural response of rats to increased 5-HT in the CNS. Bakke et al 
(1974) demonstrated a central hypotensive effect of propranolol in 
rabbits by injection of the drug into the cerebral ventricles.
In a study in man Taylor et al (1979) showed that cerebro-spinal fluid 
(CSF)/ plasma ratios were higher for propranolol than for atenolol. 
Neil-Dwyer et al (1981) carried out a study of twenty-one neurosurgical 
patients to determine the extent which chronically administered beta- 
blockers crossed the blood-brain barrier and entered brain tissue and
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the CSF. Three lipophilic drugs, propranolol, oxprenolol and metoprolol 
and the hydrophilic drug atenolol were studied. The concentration in the 
CSF of the three lipophilic drugs approximated to the free drug plasma 
concentrations and was a poor predictor of brain concentrations. The 
lipophilic drugs appeared in brain tissue at concentrations between ten 
and twenty times greater than atenolol. The brain-plasma ratio for 
propranolol was 26, for oxprenolol 50, for metoprolol 12 but only 0.2 
for atenolol.
Roubicek (1976; 1977) found characteristic changes in the 
electroencephalogram in patients given single doses of propranolol and 
pindolol which further confirms central penetration of these drugs. The 
location of the changes suggested effects on corticothalamic and deeper 
structures.
One of the first reports to cause concern about adverse psychiatric 
effects was that of Waal (1967). She became concerned when two patients 
taking propranolol committed suicide. She subsequently either reviewed 
the casenotes or interviewed a series of eighty-nine patients who were 
receiving propranolol for the treatment of cardiac arrythmias. Twenty- 
eight of this group showed some evidence of depression. Depression was 
commoner with prolonged administration and higher dosages. Subsequent 
examination of this group raised doubts about the link between 
propranolol and depression (Simpson and Waal-Manning, 1971). One of the 
suicides had a past history of depression accompanied by threats of 
suicide; the other was also on reserpine. In fifteen patients depression 
was diagnosed on the basis of "irritability, insomnia, nightmares, lack 
of drive and energy". Sedation and vivid dreams are recognised side-
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effects of propranolol and patients may have been suffering from these 
symptoms rather than from a depressive illness. There was no comparison 
group to control for other relevant factors such as the presence of 
serious physical illness.
Fitzgerald (1967) reported the results of post-marketing surveillance of 
propranolol which suggested an incidence of drug-induced depression of 
only 0.1%.
Petrie et al (1982) described three patients who developed depression 
which met standardised criteria (DSM-III,(American Psychiatric 
Association, 1980)) for major depressive disorder. In all patients 
depression developed after an increase in dose of medication and 
remitted within days of withdrawal of treatment. One patient had a 
history of depression necessitating psychiatric treatment; another had a 
significant family history of depressive illness.
Avorn et al (1986) approached this issue by examining Medicaid
prescribing records of a large cohort of patients, using prescription of
tricyclic antidepressants as an index of depression. Tricyclic usage was
compared in patients on any of seven different antihypertensive agents. 
In order to control for the effects of chronic illness, rates of 
antidepressant use were examined in patients on insulin or oral 
hypoglycaemic agents. Use of a tricyclic was significantly higher in 
patients on beta-blockers (23% in a two year period) than in those on 
hydralazine or hypoglycaemics (both 15%) and methyldopa or reserpine 
(both 10%). These differences could not be accounted for by differences
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in age or sex or the co-existence of other cardiac disease. Prescription 
of tricyclics may not however be a true reflection of depressive illness 
as such but may be indicative of the presence of central nervous system 
side-effects such as fatigue, drowsiness and malaise which might have 
prompted a trial of antidepressants.
Assessment of the psychiatric effects of antihypertensive drugs was 
carried out by Mann (1977; 1981) as part of the Medical Research Council 
(MRC) study of the treatment of mild hypertension. Patients were 
allocated to treatment with propranolol up to a maximum dose of 240 
mg/day, bendrofluazide 5 mg twice daily or placebo. The psychiatric 
state of the patients was assessed by the General Health Questionnaire 
(Goldberg,1978) on four occasions between recruitment and the completion 
of one year in the trial. A group of normotensive subjects acted as a 
control group. Trial participants were found to have lower levels of 
psychiatric morbidity than controls as the trial progressed. Medication, 
whether propranolol, bendrofluazide or placebo, had no influence on 
psychiatric morbidity. The improvement in psychiatric status in treated 
patients was thought to be due to the favourable effects on those prone 
to psychiatric symptoms of regular attendance at a clinic and contact 
with caring professional staff.
There are a number of reports of acute brain syndromes occurring in 
patients on beta-blockers. Fraser and Carr (1976) described two patients 
who became acutely unwell with symptoms of delusional thinking, auditory 
hallucinations and agitation. One of the patients also exhibited 
disorientation, ataxia and clumsiness. Symptoms had their onset within 
days of commencing on propranolol and cleared completely within a week
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of drug withdrawal. Remick et al (1981) described a mentally retarded 
woman who developed symptoms of agitation, insomnia, emotional lability, 
disorientation and hallucinations shortly after commencing on a low dose 
of propranolol. Her symptoms remitted rapidly after drug discontinuation 
and reappeared on further administration. A similar presentation was 
described in a patient on propranolol by Voltolina et al (1971). Stienert 
and Pugh (1979) described two patients who developed schizophrenia-like 
symptoms shortly after their dose of beta-blocker was increased. One 
patient was on propranolol and the other on oxprenolol. Neither patient 
had a past history of mental illness, although one had a strong family 
history of schizophrenia. In both, symptoms remitted shortly after 
discontinuation of beta-blocker. A patient described by Viadero et al 
(1983) developed vivid dreams and lapses of short-term memory two days 
after commencing on atenolol. Within two weeks he became markedly 
confused, aggressive and violent. His symptoms settled within two days 
of admission to hospital. Topliss and Bond (1977) reported on a 71 year 
old female who became confused, paranoid and restless with jerky, 
involuntary movements after being given propranolol as treatment for 
symptoms of hyperthyroidism. Her symptoms cleared six hours after 
discontinuation of propranolol. There was no other apparent explanation 
for her mental deterioration. She had a past history of depression.
Helson and Duque (1978) reported the case of a twelve year old girl 
suffering from both lymphoma and hypertension who became disorientated 
and agitated and then comatose with hyperreflexia three days after 
commencing on propranolol. Her symptoms cleared completely three days 
after the drug was stopped. Whitlock and Bonfield (1980) described a 
sixty year old man who developed delusions, visual hallucinations and
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disturbed sleep after being on propranolol for six months. He had a long 
history of heavy drinking. His symptoms remitted twelve days after 
admission to hospital, two days after propranolol was withdrawn. Gershon 
et al (1979) reported on a young woman who was a volunteer in a study of 
the physiological effects of propranolol. As the dose of propranolol was 
increased her mental state deteriorated. She initially experienced 
irritability and vivid nightmares and then developed auditory 
hallucinations, delusions, depression and poor concentration. All her 
symptoms cleared within a day of stopping the drug. Russell et al (1979) 
described the case of a young man with a history of head injury and 
encephalitis who developed generalised seizures after being given 
atenolol.
Most of the cases of severe mental disorder occurred in patients in whom 
there were other possible predisposing or precipitating factors, such as 
a past psychiatric history, the presence of coincident physical disease 
or, in one case, a strong family history of mental illness. This 
suggests that the mental illness was either coincidental with no causal 
relationship to drug treatment or that beta- blockers rarely produce 
florid psychiatric or neurological symptoms in the absence of some other 
factor which renders the patient vulnerable to these. Although the 
majority of reports are concerned with patients on treatment with 
propranolol, it is of interest that hydrophilic beta-blockers such as 
atenolol may also cause acute psychiatric disorder.
An interesting side-effect of beta-blockers is the experience of visual 
hallucinations. Hinshelwood (1969) described the case of a fifty-three 
year old man who developed frightening visual hallucinations after
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commencing on propranolol. These ceased ten days after drug 
discontinuation and reappeared on subsequent administration. Fleminger 
(1978) found visual perceptual disorders in eleven out of a group of 
sixty-three patients on propranolol. Six patients experienced visual 
hallucinations; visual illusions occurred in ten. All these symptoms 
occurred in either a hypnogogic or hypnopompic state. They were often 
accompanied by nightmares and vivid dreams. The onset occurred in four 
patients one week after an increase in dose.
Sleep disturbance has long been recognised as a side-effect of beta- 
blockers (Paykel et al, 1982). Betts and Alford (1983) found disturbed sleep 
with the lipophilic drugs propranolol, metoprolol and pindolol but not 
with atenolol which is hydrophilic. Subjective effects occurred without 
marked EEG changes.
ANGIOTENSIN CONVERTING-ENZYME INHIBITORS
The angiotensin converting-enzyme inhibitors, or A.C.E. inhibitors, are 
one of the most recently introduced groups of antihypertensive agents.
The first drug of this group to come into clinical use was captopril 
(Atkinson and Robertson, 1979). Captopril contains a sulphydryl group 
and it is thought that this part of the molecule is responsible for some 
of the side-effects of captopril such as rashes, taste disturbances, 
proteinuria and Guillane-Barre neuropathy. This led to a search for a 
non-sulphydryl-containing A.C.E. inhibitor and to the development of 
enalapril (Gavras et al, 1981). Enalapril has subsequently been shown to
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be associated with a lower incidence of taste disturbances and rash. 
Enalapril has not been associated with leucopenia (Todd and Heel, 1986). 
A recently recognised side-effect is a dry cough which has been reported 
with both enalapril and captopril (Coulter and Edwards, 1987). This is 
usually severe enough to prompt withdrawal of treatment. The mechanism 
is unknown but possible mediators include bradykinin and prostaglandin.
The most likely mode of antihypertensive action is inhibition of the 
conversion of the inactive decapeptide angiotensin I into the 
octapeptide angiotensin II, a potent pressor agent. This leads to 
increased plasma renin activity and decreased levels of angiotensin II. 
Reduced levels of angiotensin II will lead to decreased blood pressure 
mainly by decrease in total peripheral resistance. This is acheived 
without significant change in heart rate or cardiac output. It has been 
shown that cereral blood flow is preserved when arterial pressure is 
lowered by A.C.E. inhibitors and that this effect may be due to a shift 
in the limits of cerebral blood flow regulation towards lower blood 
pressure values (Waldemar and Paulson, 1989). Angiotensin II increases 
pre-junctional release of noradrenaline in response to sympathetic 
stimulation and the pressor effect of this can be blocked by captopril 
and enalapril. Captopril also leads to reduction in circulating levels 
of aldosterone. This effect is unlikely to be critical for the anti­
hypertensive action as some studies have shown that aldosterone levels 
increase during prolonged captopril treatment despite continuing low 
levels of angiotensin-II (Edwards and Padfield, 1985).
There are to date few studies of the psychological effects of the A.C.E. 
inhibitors. The subject is one of great interest to psychiatry.
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Angiotensin converting enzyme is present in the brain and there is 
evidence that it may also play a role in the metabolic degradation of 
met-enkephalin, one of the so-called "endogenous opiods" (Benuck and 
Marks ,1979; Erdos et al,1978). A study by Stine et al (1980) sugested 
that captopril might inhibit the in situ metabolism of met-enkephalin in 
rats when it is administered directly into the cerebral ventricles.
The potential for central effects depends on the ability of A.C.E. 
inhibitors to penetrate the brain. One study in rats found no evidence 
that captopril administered intravenously entered the central nervous 
system (Heald and Ita, 1977).
With regard to observed effects in man, Zubenko and Nixon (1984) 
described three patients in whom elevation of mood appeared to be 
related to the administration of captopril. Two of the patients were 
elderly men suffering from congestive cardiac failure in whom captopril 
was substituted for hydralazine and diuretics. The first patient had 
been troubled with typical depressive symptoms in the weeks prior to 
starting on captopril. These symptoms disappeared on administration of 
captopril. The second patient felt better when a small dose of captopril 
was commenced but developed agitation, insomnia and delusional thinking 
on higher doses. The third patient was a forty-four year-old woman 
admitted to a psychiatric hospital suffering from psychotic depression. 
Captopril was prescribed as treatment for hypertension. This was 
followed by an improvement in her symptoms in the four days following 
commencement of the drug which was maintained despite reduction in 
dosage over several days and then discontinuation. Goldblatt and Bryer 
(1987) described the case of a patient with Huntington’s disease who
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became bed-bound, uncommunicative, rigid and incontinent. No other cause 
was found for her symptoms which remitted five days after drug 
discontinuation. It was suggested that inhibition of angiotensin 
converting enzyme in the brain may have been responsible as it is known 
that this enzyme is diminished in the corpus striatum and substantia 
nigra of patients with Huntington’s disease (Arregui et al, 1979).
THIAZIDE DIURETICS
Thiazide diuretics are among the most widely used antihypertensive 
agents. Their hypotensive effect is acheived by lowering of intravascular 
volume and reduction of peripheral vascular resistance by diminishing 
the responsiveness of vascular smooth muscle to noradrenaline (Laurence 
and Bennett, 1987).
Concern has been expressed about the metabolic effects of thiazides such 
as potassium depletion, adverse effects on serum lipid concentrations 
and hyperuricaemia (Oliver, 1983). A substudy of the M.R.C. study 
examined the effect of bendrofluazide on ventricular ectopic beats and 
found a significant excess in patients who had been on treatment for an 
average of two years (Medical Research Council Working Party, 1983).
While it has not been conclusively demonstrated that this was due to 
potassium depletion, this possibility remains (Robertson, 1987). Another 
substudy found an unexpectedly high incidence of erectile impotence in 
men on bendrofluazide (Medical Research Council Working Party, 1981). 
Perhaps in view of the peripheral actions of these drugs, there have 
been no listed trials examining their effects on the central nervous 
system.
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ANTI-HYPERTENSIVE MEDICATION AND "QUALITY OF LIFE"
A recent development in the study of the psychological effects of 
antihypertensive drugs has been to broaden the search for adverse 
effects into areas which may be conceptualised in terms of impaired 
quality of life rather than the presence of formal psychiatric disorder. 
Quality of life has usually been assessed in two broad areas. The first 
of these is subjective well-being, which may be judged in terms of 
freedom from physical or mental symptoms. The second area concerns 
performance and satisfaction in normal social roles such as work, family 
life and leisure.
Quality of life is an inherently complex, nebulous and idiosyncratic 
entity. This is captured very well in a poem entitled "Ode to 
Propranolol" (Benson, 1985). The poet, who is a physician, describes how 
his emotional responses to the beauties of art and nature have been 
blunted by this drug, and goes on to question whether the benefits of 
medication are not outweighed by what he has lost. Assessment of all 
areas contributing to happiness and well-being in a group of patients 
would be highly laborious and research must begin by reducing the field 
of enquiry to areas which are of manageable proportions, broad 
applicability and demonstrable validity.
The largest and most comprehensive study of the effects of drug 
treatment of hypertension on quality of life performed to date is that 
of Croog et al (1986). 626 patients were recruited, of whom 486 were
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followed up over twenty-four weeks of active treatment. The patients 
were white men in full-time employment with mild to moderate 
hypertension (diastolic blood pressure 92-109 mmHg). On recruitment, 
patients were placed on placebo for four weeks. Baseline assessment was 
performed at the end of this period and patients were then randomly 
allocated to receive therapy of standard doses of either captopril, 
methyldopa or propranolol. If blood pressure control was unsatisfactory 
after eight weeks hydrochlorthiazide was prescribed. Quality of life was 
assessed by well-validated rating scales relating to general well-being, 
physical symptoms, sleep dysfunction, sexual functioning, work 
performance and satisfaction, emotional state, social participation, 
life satisfaction and cognitive impairment. Comparisons were made 
between scores at baseline and at twenty-four weeks.
At the end of the study, the captopril patients were rated better than 
the methyldopa group in respect of general well-being, physical 
symptoms, sexual dysfunction, work performance and satisfaction with 
life. Patients on propranolol rated better than those on methyldopa in 
terms of work performance. Scores of the captopril group were favourable 
with regard to general well-being, physical symptoms and sexual 
dysfunction when compared to the propranolol group.
Patients receiving captopril were least likely to withdraw from 
treatment because of adverse effects (8% versus 20% for methyldopa and 
13% for propranolol). Significantly fewer patients on propranolol (22%) 
required treatment with a diuretic compared to captopril (33%). 28% of 
the methyldopa patients required diuretic treatment which was not 
significantly different from the other groups.
This study entailed enormous effort. A large cohort of patients was 
followed up over a lengthy period of treatment. The homogeneity of the 
group in terms of demographic background means that the results cannot 
be readily extrapolated to populations dissimilar with respect to sex, 
race and employment status. Where statistically significant differences 
were found these were often small and unlikely to be of clinical 
importance. No effort was made to obtain an account from relatives of 
changes in patients’ happiness and behaviour. Specific side-effects of 
angiotensin-converting enzyme inhibitors, such as cough, were not 
addressed. A recently introduced drug, captopril was compared with two 
old-established agents. It may have been more appropriate to compare 
captopril with newer and increasingly popular drugs such as the 
hydrophilic beta-blockers which may have less tendency to cause 
psychological side-effects.
Dahlof et al (1985) assessed quality of life as part of a trial of the 
antihypertensive effects of enalapril. Patients were withdrawn from 
their previous medication and placed on placebo for four weeks. They 
were then treated with enalapril for twelve weeks. Quality of life was 
assessed by a new scale devised by one of the authors. Scores on the 
scale improved when patient were changed to placebo and were not 
impaired by subsequent treatment with enalapril. Unfortunately, neither 
this paper nor another describing the scale contains much information 
about its structure and scoring (Jern, 1985). It is therefore difficult 
to assess what significance should be inferred from changes in scores 
and whether the instrument is, indeed, a valid measure of quality of 
life.
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Jachuck et al (1982) assessed quality of life in seventy-five patients 
on antihypertensive medication using questionnaires given to patients, 
their general practitioners and a relative or close companion. Each 
informant was asked to assess if the patient was, overall, improved, 
worse or unchanged since commencing on therapy. In addition patients and 
relatives completed a questionnaire which inquired into important 
aspects of well-being.
Thirty-six patients received beta-blocking drugs (nineteen also received 
diuretics), eighteen received methyldopa (thirteen were also on 
diuretics), nine received diuretics alone and six patients were on other 
antihypertensive agents.
The overall assessment of the physicians was that all seventy-five 
patients had improved. Of the patients themselves, thirty-six felt 
better, seven felt worse and thirty-two rated themselves as being 
unchanged. In striking contrast, the assesment of relatives was that, 
with one exception, the patient was worse since starting on therapy.
Deteriorations highlighted by the questionnaire included undue 
preoccupation with sickness, irritability and decline in energy, general 
activity and sexual activity.
This study is interesting as it highlights large discrepancies in how 
the condition of the patient is perceived by different observers. 
Especially notable is the lack of awareness on the part of physicians of 
deterioration in the quality of life of their patients. A major strength
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of the paper is that it sought information from an independent 
informant. The retrospective study design does not allow one to draw 
conclusions as to whether the decline in quality of life was due to 
treatment itself or to other factors such as illness labelling.
Patients were on a variety of different drugs; the duration of treatment 
was not specified. The existence or otherwise of hypertension-related 
physical morbidity was not mentioned. There are therefore many factors 
which could explain a decline in quality of life in this group some of 
which are independent of the processes of diagnosis and treatment.
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ANTIHYPERTENSIVE DRUGS AND MENTAL FUNCTIONING
Many antihypertensive drugs penetrate the central nervous system; an 
important potential adverse effect therefore is impairment of 
intellectual functioning. This issue deserves attention as patients will 
usually be expected to remain on treatment for many years if not for 
life. Small decrements in mental ability may be tolerable in short term 
treatment. The imposition of impairment, even of a minor nature, is less 
acceptable in the long term. In addition, there are certain occupations, 
such as airline pilots and air traffic controllers, in which it is 
essential to maintain optimum levels of mental functioning.
Patients whose occupation demands a high level of mental acuity may be 
more aware of mental impairment. Adler (1974) described five case 
reports of professional patients who experienced lapses of memory, 
problems with reading and difficulty with simple calculation while on 
methyldopa. In all cases symptoms disappeared promptly on 
discontinuation of the drug.
Most of the research done in this area has concerned the beta-blocking 
drugs, although a few papers also mention methyldopa and other drugs.
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BETA-BLOCKERS
SINGLE DOSE STUDIES
Bryan et al (1974) examined the effects of propranolol on tests of 
visual function and central nervous system activity. Six normal 
volunteers received propranolol at doses of 40mg and 80mg. There was no 
effect on visual function but slowing of reaction times was found after 
both doses of drug.
Goldman et al (1969) studied the effects of single doses of alprenolol 
on simulated driving performance in six healthy volunteers. There was no 
difference in driving errors when performance after medication was 
compared with that following placebo. Bayliss and Duncan (1975) studied 
the effects of single doses of atenolol (50mg or lOOmg) and methyldopa 
(250mg or 500mg) on tests of reaction time (RT) and critical flicker 
frequency (CFF) and on levels of drowsiness as assessed by visual 
analogue scale, in six normal volunteers. Methyldopa caused an increase 
in reaction time, this being more marked at the higher dose, and an 
increase in subjective drowsiness. Atenolol had no effect on any of the 
variables measured.
Ogle et al (1976) investigated the effects of high doses of propranolol 
and oxprenolol on pursuit rotor performance (PRP), reaction time and 
critical flicker frequency. There was no discernible effect on RT and 
CFF. Impairment on PRP was found but was attributed to a peripheral 
effect on skeletal muscle. Levander and Gillner (1982) studied the
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effects of propranolol (40mg) and metipranolol (5 and 20mg) in twelve 
normal volunteers using a variety of assessments (digit span, perceptual 
maze, vigilance measures, pain perception and CFF). No decreases in 
performance were noted.
Similar conclusions were reached by Lader et al (1972) who found no 
impairment on a variety of neurophysiological and behavioural measures 
after administration of propranolol (120mg) or sotalol (240mg) to six 
normal subjects.
Salem and McDevitt (1983) studied the effects of single doses of 
atenolol (50mg, lOOmg, 200mg and 400mg) on performance of tests of two 
flash fusion threshold (TFFT), simple reaction time (SET), symbol digit 
modalities test (SDMT), and the Gibson Spiral Naze Test (GSMT) on six 
normal volunteers. In comparison with placebo, performance was poorer on 
all tests with the exception of the GSMT. A later study with a similar 
design using propranolol at doses of 40mg, 80mg, 160mgand 320mg produced 
comparable results (Salem and McDevitt, 1984).
STUDIES IN HYPERTENSIVE PATIENTS
Solomon et al (1983) studied the effects of propranolol and methyldopa 
on tests of verbal and non-verbal memory. Four groups of patients were 
studied; 1) hypertensive patients on methyldopa and diuretic (10 
patients); 2) hypertensives on propranolol and diuretic (11 patients);
3) hypertensives on diuretic alone (12 patients) and; 4) 
nonhypertensives on propranolol (8 patients, on treatment for migraine,
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angina, arrhythmias and familial tremor). When compared with the 
diuretic group patients on methyldopa and propranolol scored poorly on 
tests of verbal memory. Performance on tests of visual memory was not 
impaired. This study therefore raises the possibility that verbal memory 
can be impaired by propranolol and methyldopa. The diuretic-only group 
acted as a control for the presence of hypertension. The fact that 
patients in this group were adequately controlled on single drug 
treatment implies that their hypertension was of lesser severity. In 
addition some of the non-hypertensive patients had conditions such as 
angina which may be associated with cerebro-vascular disease. In brief, 
the poor performance of the propranolol and methyldopa-treated patients 
may be to some extent attributable to the severity of their underlying 
disease.
Fransceschi et al (1982) compared cognitive performance in fifteen 
normotensive patients, seventeen newly-diagnosed, untreated 
hypertensives and twenty-two treated hypertensives. Both hypertensive 
groups performed poorly on a variety of tests. Patients on anti­
hypertensive drug treatment (diuretics plus propranolol or reserpine in 
four and three patients respectively) did poorly on tests of attention. 
This study is of interest but used a small sample and a large number of 
comparisons. Some of the observed differences may have arisen by chance. 
The design of the study does not allow exclusion of the possibility that 
performance of the hypertensive patients was impaired by minor 
cerebrovascular disease not detectable on routine neurological 
examination.
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Madden et al (1986, 1988) studied the effects of atenolol and 
propranolol in a group of twenty-six men with mild hypertension.
Atenolol was commenced at a dose of 50mg which was increased to lOOmg if 
response was inadequate; propranolol was used at a dose of 40 mg 
increasing to 80 mg. After two weeks on medication or placebo, a test 
was administered which was based on a memory search paradigm. No 
differences were found when performance on drug treatment was compared 
to placebo.
A.C.E. INHIBITORS
Lichter et al (1986) examined the effects of atenolol and enalapril on 
memory in patients with essential hypertension. All patients completed a 
battery of associate learning tests after two weeks on placebo. They 
were then randomly allocated to receive atenolol (13 patients) or 
enalapril (12 patients) and retested after sixteen weeks of active 
treatment. When compared to placebo, the enalapril patients showed no 
changes in memory function, whilst there was a mild memory deficit in 
those on atenolol.
Olajide and Lader (1985) carried out a double -blind cross-over trial of 
the psychotropic effects of enalapril in twelve normal subjects treated 
with enalapril 20mg daily for fourteen days. Subjects were assessed by 
physiological measures (electroencephalogram, auditory evoked responses, 
skin conductance and CFF), psychological measures (digit-symbol 
substitution, symbol copying, auditory reaction time and tapping rate) 
and subjective ratings of mood and bodily symptoms. Increased alertness
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on enalapril was suggested by an increase in auditory evoked responses 
and tapping rate. Despite this nine subjects complained of tiredness 
on enalapril compared to only two on placebo. No other drug effects were 
noted.
Frcka and Lader (1988) examined the psychotropic effects of enalapril 
20mg, propranolol 160mg and atenolol 50mg each given daily for eight 
days to twelve normal voluteers. Assessments were similar to the 
preceding study with the addition of a test of verbal memory and a sleep 
questionnaire. Electroencephalogram changes were noted at the end of 
the propranolol phase but were not consistent in the case of the other 
drugs. Reaction time, symbol copying and verbal memory were 
significantly impaired with propranolol. Verbal memory was mildly 
affected by atenolol. Subjects showed improvements in tapping rate but 
impaired verbal memory on enalapril. Enalapril was associated with a 
feeling of calmness but also an increase in complaints of headache. 
Complaints of drowsiness were commoner with propranolol.
CALCIUM-CHANNEL BLOCKERS
The calcium-channel blockers are increasingly used in treatment of 
hypertension, effort angina and angina due to coronary artery spasm. 
Their mode of action is antagonism of calcium influx through the slow 
channel of the cell membrane. This leads to dilatation of the coronary 
and peripheral arteries with resulting reduction in systemic vascular 
resistance and improvements in myocardial oxygen supply. Cardiac pumping
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ability is improved by decreased afterload (Sorkin and Clissold, 1987).
There is increasing interest in the effects of calcium channel blockers 
on the central nervous system. Walden et al (1985) found that verapamil 
could suppress epileptiform activity in an in vitro model of epilepsy. 
Larkin et al (1988) reported a pilot study of the use of nifedipine in a 
group of patients with intractable epilepsy, with approximately half of 
the patients achieving a greater than fifty percent decrease in 
seizures over a three month follow-up period.
Calcium antagonists have also been used in the treatment of various 
disorders characterised by abnormal movements. Barrow and Childs (1986) 
described a dramtic improvement in neuroleptic-induced tardive 
dyskinesia in two patients given verapamil. Ley et al (1988) carried out 
a small double-cross-over study of the effects of diltiazem on tardive 
dyskinesia and found a reduction of abnormal movements on active 
treatment. The mechanism of this effect is unknown. An anti-dopaminergic 
effect has been postulated although Dogget and Mercurio (1989) found no 
evidence for such an effect in experimental animals.
Calcium antagonists have been reported to cause cerebral vasodilatation 
in animal experiments (Takenaka and Handa, 1979; Yamamoto et al, 1983). 
Thuillez et al (1984) reported that oral nicardipine increased carotid 
artery diameter and blood flow in humans. There are however reports of 
cerebral and retinal ischaemia being caused by nifedipine (Nobile-Orazio 
and Sterzi, 1981; Pitlik et al, 1983). The proposed mechanism is "steal” 
of blood flow from areas served by atheromatous vessels which do not 
respond to the vasodilating effect.
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It has been suggested that calcium influx to cells may produce cellular 
injury during reperfusion following cerebral injury (Borzeix and Cahn, 
1983; Grotta et al, 1984; Gelmers, 1987). The calcium antagonist, 
nimodipine has been shown to improve cerebral reperfusiion and survival 
after ischaemic damage in cats (Kazda et al, 1979) Similar results with 
regard to blood flow were obtained in dogs by Iwatsuki et al (1987). 
Sakabe et al (1986), in a study in dogs found improvements in post- 
ischaemic cerebral blood flow but no associated improvement in 
neurological recovery. A study in patients with multi-infarct dementia 
using nimodipine found no evidence of benefit as assessed by clinical 
ratings, psychometric testing and sequential magnetic resonance imaging 
(Besson et al, 1988).
A large British study assessed the effect of oral nimodipine on outcome 
after subarachnoid haemorrhage (Pickard et al, 1989). Patients on 
nimodipine had a significantly lower incidence of cerebral infarction 
and poor outcome (death, vegetative state or severe disability). The 
mechanism of the beneficial effect was unclear. It was postulated that 
the drug may have acted to prevent vasospasm in small cerebral 
arterioles or had an undetermined effect on neuronal functioning which 
served to diminish damage.
37
ASSESSMENT OF PSYCHIATRIC SIDE-EFFECTS OF ANTIHYPERTENSIVE DRUGS
The realm of possible psychological effects of anihypertensives is one 
which is potentially very large. It ranges from formal psychiatric 
illness to mild effects which may be considered under the rubric of 
"quality of life". In addition to psychiatric well-being, quality of 
life embraces the areas of intellectual functioning and physical well­
being. Quality of life may also be considered in terms of ability to 
perform satisfactorily, and derive enjoyment from, the important 
activities of life such as work, marriage, family life and leisure.
Assessment of psychological well-being in this situation is therefore 
potentially very complex. The decisions about which assessments should be 
performed entailed finding a compromise between the wish to be 
comprehensive and a recognition of constraints on the time available 
for both staff and patients. It was felt that assessment should cover 
the areas of a) psychiatric symptoms, b) social functioning and c) 
intellectual functioning. The patient group under study was one that was 
to be involved in a range of physical investigations as well as 
psychological assessments. It was estimated that a maximum time of 
around thirty minutes would be available. In addition, time spent 
waiting would be available for the completion of self-report 
questionnaires.
The studies were designed to test the following hypotheses:-
a) that antihypertensive drugs have adverse effects on mental well-being
b) that antihypertensive drugs cause impairment in functioning in normal 
social roles
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c) that antihypertensive drugs cause decrements in mental faculties such 
as memory and concentration.
Psychiatric symptoms.
Psychiatric symptoms were principally assessed by the sixty-item General 
Health Questionnaire (Goldberg, 1978). This is a self-administered 
questionnaire which was developed to allow detection of psychiatric 
morbidity in general practice and general medical populations. Four 
seven-item subscales have been derived from the main questionnaire which 
allow examination of the areas of somatic symptoms, anxiety and 
insomnia, social dysfunction and severe depression.
Assessment of the validity of the questionnaire was carried out using a 
structured psychiatric interview. The interview used was the Clinical 
Interview Schedule (Goldberg et al, 1970). Again, this was developed for 
use in the general population. The author received special training in 
its use. The interview is semi-structured, is fairly brief to administer 
in the asymptomatic patient and is readily acceptable to non-psychiatric 
patient populations. It allows a reliable and valid asessment of "case" 
status and can be used to obtain a psychiatric diagnosis in terms of the 
ninth edition of the International Classification of Diseases (W.H.O., 
1978).
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Social functioning.
This was assessed using the self-report form of the Social Adjustment 
Schedule (Weissman and Bothwell, 1976; Weissman et al, 1978). This scale 
was developed to measure social adaptation in psychiatric populations. 
Cooper et al (1982) demonstrated the validity of the scale in a British 
population. They showed that the scale was sensitive to changes in 
mental state in a group of non-psychiatric patients who showed levels of 
psychiatric morbidity similar to the general population. Age and social 
class had no influence on overall scores or scores in the different 
subscales. The scale investigates ability to fulfil social roles in the 
areas of work, spare time activities and marriage and family life. 
Responses to questions are weighted according to level of maladjustment. 
The complete questionnaire is not applicable in every patient. An 
overall social adjustment score is obtained by calculating the average 
of all responses.
Intellectual Functioning.
Limitations on available time meant that assessment of intellectual 
functioning had to be confined to selected areas. The trial was carried 
out in three different hospitals thus precluding the use of non-portable 
equipment. It was decided to include tests of verbal memory, non-verbal 
memory, and attention and concentration.
The following battery of tests was performed:
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a) Wechsler Memory Scale Subtests (Wechsler, 1945). i) "Logical memory" 
tests ability to recall verbal material, ii) "digits forward" assesses 
passive apprehension of new information, iii)"digits backward" tests 
immediate memory and iv) "associate learning" tests ability to learn new 
verbal material.
b) Complex Figure Test (C.F.T.) (Rey, 1942; Taylor, 1969). The subject 
first copies a complex abstract figure. On completion, the figure is 
removed and he attempts to reproduce it from memory. Reproduction is 
then repeated after twenty-five minutes. The test assesses 
constructional abilities and the ability to memorise and organise 
complex non-verbal information. Each component of the figure was rated 
according to accuracy of reproduction and position in the figure and the 
scores summated to yield an overall score as described in Lezak (1983).
Tests a) and b) exist in two comparable forms. Subjects were randomly 
allocated to receive one or the other at the time of initial testing and 
received the alternative form after a period of active treatment.
c) Digit Symbol Substitution Test (Wechsler, 1955). This is a subscale of 
the Wechsler Adult Intelligence Scale. It assesses psychomotor speed
and coordination.
d) Paced Auditory Serial Addition Task (P.A.S.A.T.) (Gronwall and 
Sampson, 1974; Gronwall and Wrightson, 1974). The subject listens to a 
taped presentation of sixty randomised digits and attempts to add each 
digit to the one immediately preceding it. His verbal responses are
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recorded by the examiner. The series of digits is presented twice. On 
first hearing the digits are presented at two second intervals and on 
second hearing at 1.6 second intervals. The test assesses speed and 
efficiency of information processing.
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STUDIES OF THE PSYCHOLOGICAL SIDE-EFFECTS
OF ANTIHYPERTENSIVE MEDICATION
Three studies performed by the author will be described. The first is a 
pilot study carried out to investigate the psychological effects of 
captopril. The results of this trial provided the stimulus for the other 
two. These investigations were of single drug treatment in patients with 
mild-moderate hypertension. The larger trial of the two looked at the 
effects of atenolol and enalapril on a number of measures of 
psychological well-being and social functioning. The smaller study was 
of similar design but investigated the effects of propranolol and 
nicardipine.
STUDY I : PSYCHIATRIC SIDE-EFFECTS OF CAPTOPRIL 
INTRODUCTION
This trial was stimulated by a succession of anecdotal reports of 
spontaneous comments by patients of an enhanced sense of well-being 
after commencing on captopril as treatment for hypertension. These were 
usually patients previously subjected to complex drug regimes. Whilst a 
greater feeling of well-being may be an advantage, a definite 
euphoriant effect might create problems for patients.
The possibility of a mood-elevating effect is of theoretical and 
practical interest to psychiatry. As discussed above there is evidence
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from animal studies that angiotensin converting enzyme may involved in 
the metabolism of met-enkephalin, one of the "endogenous opioids" and 
that centrally-administered captopril may inhibit breakdown of this 
peptide. If converting enzyme inhibitors were shown to have such an 
effect then further insight into the biochemical control of mood might 
be obtained along with the possibility of novel treatments for 
depression.
The hypothesis to be tested therefore was whether angiotensin- 
converting enzyme inhibitors create improvements in mental well-being 
either by relieving psychiatric symptoms or by creating an abnormal 
elevation of mood.
PATIENTS
Eight patients with moderately severe hypertension entered the study 
after informed consent was obtained. There were four women and four men; 
their mean age was 51 years. Patients were excluded if there was a 
history of cerebrovascular accident; evidence of organic brain damage or 
impairment; a history of schizophrenia or affective psychosis; if they 
had received any psychotropic medication other than benzodiazepines 
within three months of entry; if they had heart failure; or had severe 
renal impairment.
Apart from captopril, the only antihypertensive drugs used during the 
study were atenolol and bendrofluazide. At least four weeks before the 
start of the trial, antihypertensive therapy was standardised and 
remained fixed for each subject throughout. One patient also received
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diazepam 5mg/day for four weeks before the start and throughout the 
study.
PROTOCOL
The study period was 12 weeks with patients seen at 0, 3, 6, 9 and 12 
weeks. At the start (i.e. at least 4 weeks after standardization of 
atenolol and bendrofluazide doses), patients were randomly allocated to 
receive captopril 25 mg three times daily or matching placebo for the 
first 6-week period, with crossover to placebo or captopril respectively 
for the second 6-week period.
At each visit, supine blood pressure and pulse rate were measured.
Specimens were sent for estimation of serum electrolytes, full blood 
count and urinary protein. At weeks 3 and 9, after 30 minutes lying 
supine and two hours after dosing, blood was drawn for measurement of 
plasma active renin concertration and angiotensin II.
Patients and observers remained unaware of the treatment code although 
this was available in sealed envelopes in the event of an emergency.
Psychological assesment was performed at weeks 3, 6, 9, and 12, before 
blood pressure measurements and blood samples were obtained. At these 
visits a tablet count was made to assess compliance.
Psychiatric state was assessed using the sixty-item General Health
Questionnaire (Goldberg, 1978). Attention and concentration were 
assessed by the Paced Auditory Serial Addition Task (Gronwall and
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Sampson, 1974). A mania rating scale was administered to record and 
quantify features of elevated mood (Young et al, 1978). Statistical 
analysis was by the Wilcoxon matched pairs test (Siegel, 1956).
RESULTS
Three of the patients received captopril before placebo; the other five 
received placebo first. No subject required intervention because of poor 
blood pressure control. There was no instance of proteinuria, 
leucopenia, electrolyte disturbance or skin rash. Taste impairment 
occurred in one patient at Week 11 while taking captopril.
Tablet counts were correct on all occasions. In all patients, plasma 
renin concentrations were higher and angiotensin II concentrations 
lower, during the period of captopril therapy. Comparing captopril with 
placebo overall, mean blood pressures were significantly lower (164/98 
mm Hg + 9/3 SEM vs 176/101 + 8/2; p < 0.05), plasma active renin was 
higher (50 + 19 micro U/ml vs 23 + 7; p < 0.05), and angiotensin II 
reduced (9.3 + 1 pg/ml vs 15.1 + 3; p < 0.05).
PSYCHOLOGICAL TESTING
GENERAL HEALTH QUESTIONNAIRE. All except one subject had higher mean 
overall scores when on captopril than when on placebo. This difference 
was statistically significant (p < 0.05) (Table 1). Analysis was further 
pursued by considering separately those subscales addressing somatic
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symptoms, anxiety and insomnia, social dysfunction and severe depression 
(Goldberg and Hillier, 1979). In all subgroups of questions, except 
those dealing with depression, average scores were higher during the 
captopril than the placebo phase. No particular symptom subgroup, 
therefore, made a disproportionate contribution to the differences in 
total score.
PACED AUDITORY SERIAL ADDITION TASK. No differences were found between 
captopril and placebo (Table 2).
MANIA RATING SCALE. No subject at any time had a score suggestive of 
abnormal elevation of mood (Table 3).
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STUDY II: ATENOLOL AND ENALAPRIL
INTRODUCTION
The purpose of this study was to assess a recently-introduced 
angiotensin converting enzyme inhibitor, enalapril, and to compare it to 
the beta-blocker, atenolol, in terms of its efficacy in the treatment of 
mild-moderate hypertension and with regard to its impact on 
psychological and physical well-being.
Enalapril lowers peripheral vascular resistance by producing decreased 
plasma levels of angiotensin II. Blood pressure is lowered without 
causing an increase in heart rate. At doses of 10 to 40 mg per day, it 
is effective in lowering blood pressure in all grades of essential and 
renovascular hypertension (Todd and Heel, 1986). In mild to moderate 
hypertension, enalapril has been shown to be as effective as 
hydrochlorothiazide (Vidt, 1984; Bauer and Jones, 1984) and the beta- 
blockers propranolol, (Enalapril in Hypertension Study Group, 1984) 
metoprolol (O’Connor et al, 1984) and atenolol (Arr et al, 1984). 
Adequate control of blood pressure has been acheived in fifty to 
seventy-five percent of patients given enalapril alone. Adequate control 
in the remainder of patients can usually be attained with the addition 
of a diuretic.
The majority of reported side-effects are mild, transient and are often 
seen in similar frequencies in patients on placebo. Those most 
frequently reported are headache, dizziness, fatigue, diarrhoea, nausea, 
rash, cough, hypotension and angioneurotic oedema.
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Patients
Patients were recruited in three centres covered by the Glasgow Blood 
Pressure Clinics namely the Vale of Leven Hospital, Glasgow Royal 
Infirmary and Glasgow Western Infirmary.
All patients sufferred from mild to moderate hypertension with supine 
blood presure of 140-220 mmHg systolic and/or 90-119mmHg diastolic on 
three occasions during a four week phase of treatment with placebo alone.
Patients with known secondary hypertension, accelerated phase 
hypertension, cerebrovascular disease, myocardial infarction within the 
previous six months, renal impairment (serum creatinine > 144 
micromol/1), a history of psychotic or major affective illness, or any 
contra-indication to either of the trial treatments were excluded.
Study Design
After a four week placebo run-in period, patients whose blood pressures 
fulfilled the criteria stated above were randomised to receive either 
enalapril or atenolol in parallel groups. The use of a parallel placebo 
group was considered but it was judged to be ethically unacceptable to 
have patients on no active medication for the duration of the trial.
Each centre had a separate randomisation process which was stratified 
for previous drug treatment. The study was conducted double-blind using 
a double-dummy technique. Treatment was continued for twelve weeks and
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patients were reviewed at two, four, eight and twelve weeks after 
randomisation. The aim was to reduce systolic blood pressure to 140 mmHg 
or less and diastolic pressure to 90 mmHg or less.
The initial dose of medication was enalpril 20 mg or atenolol 50 mg, 
each taken once daily in the morning. If blood pressure did not reach 
the stated target at four or eight weeks after randomisation, the dose 
was increased to enapril 40 mg or atenolol 100 mg each taken once daily.
The full range of assessments, as described above, was performed on each 
subject on two occasions, firstly at the end of the four week placebo 
phase and secondly after twelve weeks of active treatment. The Clinical 
Interview Schedule was administered to a random sample of patients on 
the same day as they completed a General Health Questionnaire. The 
interviewer was blind to the result of the questionnaire. Assessments 
were performed at approximately the same time of day.
In addition, subjects were seen at two, four, eight and twelve weeks for 
physical assessment. At each visit, patients were weighed and had their 
blood pressures and pulse rates recorded erect and supine in the right arm 
after fifteen minutes of rest. Blood pressure was estimated with the arm 
supported at heart level using a random zero sphygmomanometer, recording 
phase V diastolic pressure. Tablet counts were carried out at each 
visit and urinary drug assay on two occasions at four and twelve weeks 
after randomisation. Haematological and biochemical monitoring, 
including measurement of plasma renin was performed at the end of the 
placebo phase and at the end of the active treatmnet phase. The patient 
was in a supine position for thirty minutes prior to blood being
withdrawn. Subjective side-effects were assessed at each visit by the 
response to a standard, non-leading question and by a questionnaire 
based on that devised by Bulpitt and Dollery (1973) which was 
administered at the end of the placebo and active treatment phases.
Statistical Methods
The sample size was determined by the need to provide a power of 0.8 to 
detect a difference between the drugs in blood pressure response of 8/5 
mmHg with statistical significance at the 5% level. A single interim 
analysis was planned with the intention that psychological testing would 
be discontinued if clear differences (p < 0.001) between the treatment 
groups had emerged. Psychological data were analysed using the Mann- 
Whitney U test, with corresponding confidence intervals. All p values 
refer to the two-tailed significance of between-group differences.
Results
In all, 162 patients were randomised, to either atenolol (n = 76) or 
enalapril (n = 86). Their characteristics are described in Table 4. The 
groups were well-matched for important variables except for age, the 
atenolol- treated patients being on average four years older. Fifteen 
patients withdrew from the trial of whom seven were on atenolol and 
eight on enalapril. The blood pressure findings refer to the 147 
patients who completed twelve weeks of active treatment. The average 
dose of medication being taken at twelve weeks was 91mg of atenolol and 
33mg of enalapril.
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Blood pressure and pulse rate
These measurements were not carried out by the author but formed part of 
the study of the antihypertensive effects of the drugs. They will be 
reported briefly as they have some relevance to the interpretation of 
the psychiatric data.
Decreases in supine systolic and diastolic blood pressure were 
significantly greater with enalapril than with atenolol. At twelve weeks 
the mean reduction with enalapril was 19.0 (SEM 1.6) / 12.4 (1.1) mmHg,
compared to 8.8 (2.1) / 7.4 (1.2) mmHg for atenolol (p < 0.001 / p < 
0.005). With regard to standing blood pressure the the mean reduction 
with enalapril was 20.1 (1.9 ) / 12.3 (1.4) compared to 13.3 (2.2) / 9.1 
(1.4) mmHg for atenolol (p = 0.02 / p = 0.10). Adjustment for age had no 
important effect on the blood pressure responses described above. Thirty 
of the eighty-six patients (35%) randomised to enalapril achieved target 
blood pressure (140 mmHg systolic or less and 90 mmHg diastolic or less) 
at twelve weeks, compared to eleven of seventy- six patients (14%) 
randomised to atenolol (p < 0.01). Target blood presure was achieved by 
twenty-one patients taking enalapril 20 mg daily and by four patients 
taking atenolol 50 mg daily. Atenolol reduced the mean supine pulse rate 
by 16.6 (1.2) beats per minute, compared to an increase of 0.8 (1.1) 
beats per minute with enalapril (p < 0.001).
Adverse effects
Eight patients withdrew from the trial because of adverse effects which
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were attributed to treatment and another seven for reasons unrelated to 
the trial. In the atenolol group, three patients withdrew respectively 
because of tirednesss, dizziness and impotence. In the enalapril group, 
five patients withdrew because of tiredness (two patients), chest pain, 
wheeze and cold extremities. The most common volunteered side-effects 
with atenolol were tiredness (16%) and dizziness (14%). With enalapril, 
the commonest volunteered side-effects were tiredness (17%), dizziness 
(14%) and headache (8%). Cough was reported by four patients on 
enalapril and by two patients on atenolol.
Symptom questionnaires showed no significant differences in the average 
number of symptoms reported per patient (atenolol 3.2; enalapril 3.0). 
Compared to placebo, patients reported an average of 0.5 symptoms less 
during atenolol treatment and 0.1 symptoms less with enalapril (95% C.I. 
for difference : -1.0, + 0.3). As assessed by volunteered information 
and symptom questionnaires, no particular symptom occurred significantly 
more frequently with either drug.
Psychological Data
Psychological testing was performed at weeks 0 and 12 in one hundred and 
thirty four patients; of these sixty-four were on atenolol and seventy 
on enalapril. Thirteen patients did not complete the psychological 
tests. Only one patient refused to participate. The majority of the 
remainder were missed for administrative reasons. Other patients were 
excluded if they experienced life events prior to randomisation or in 
the course of the active treatment phase which were considered likely to
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affect their responses to testing. The results of the main comparisons 
are given in Table 5.
1) General Health Questionnaire (GHQ-60)
There was no significant change in GHQ-60 scores in either the enalapril 
or the atenolol group after twelve weeks of active treatment. There were 
no significant differences in scores between the groups either at 
baseline or at twelve weeks (Table 6).
The number of '’cases” (patients with scores of 12 or more) fell from ten 
to four in the enalapril group and from nine to four in the atenolol 
group (Table 7).
The Clinical Interview Schedule was administered to a randomly selected 
sub-sample of twenty-seven patients. These patients had already 
completed the GHQ-60 on the same day. Only two cases were found to have 
scores at "caseness" level on interview; these patients also scored as 
"cases” on the questionnaire. The twenty-five interview "non-cases” were 
also "non-cases” by questionnaire. The small number of cases did not 
permit a formal analysis of validity. A significant correlation between 
total scores on the interview and the total GHQ score was found using 
the Kendall Rank Correlation Coefficient (tau = 0.457, significant at 
the 0.002 level) (Table 8).
Cognitive Functioning
a) Wechsler Memory Scale. In no subtest was there a significant change
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between baseline scores an those obtained after twelve weeks of active 
treatment. There were no significant differences between groups at 
either baseline or twelve weeks (Tables 9-12).
b) Complex Figure Test. Again, there were no significant changes over 
twelve weeks and no differences between groups at either baseline or 
twelve weeks (Tables 13-15).
c) Digit Symbol Substitution Test. Scores in both groups increased 
between first and second testing. The increase in the enalapril group 
was significantly greater than in the atenolol group (p < 0.005)
(Table 16).
d) Paced Auditory Serial Addition Task.Once more, scores increased in 
both groups with a significantly greater increase in the enalapril group 
(p < 0.05) (Table 17).
Social Adjustment
Social Adjustment Schedule (Self-Report). There was no change of note in 
either treatment group and no difference between groups at first or 
second testings (Table 18).
55
STUDY III. PROPRANOLOL AND NICARDIPINE
INTRODUCTION
A smaller study of similar design to Study II was carried out as part of 
an investigation of the antihypertensive effects of propranolol and 
nicardipine and of their effects on whole body electrolytes. This study 
allowed an examination of the psychological effects of a lipophilic 
beta-blocker and a calcium-channel blocker.
The calcium-channel blocker investigated in the present study is 
nicardipine, a recently introduced member of this group. Its usefulness 
in the treatment of mild-to-moderate hypertension is now well- 
established (Brown et al, 1986; Forette et al, 1985; Taylor et al,
1985). Side-effects are mostly mild, appear to be dose-related and are 
most frequent during the first few weeks of therapy. Vasodilation- 
related effects, such as flushing, headache and oedema, occur in 
approximately one third of patients. The other common group of side- 
effects are cardiovascular with symptoms such as increased anginal 
pains, exercise-induced hypotension, palpitions and dyspnoea.
Patients
Thirty patients were recruited from a population of general practice 
patients. Patient characteristics are described in Table 19. Exclusion 
criteria were similar to those described in Study II.
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Design
The study employed a double-blind parallel design. Patients were taken 
off previous antihypertensive medication and placed on placebo for a 
four week washout phase. At the end of this phase and prior to starting 
active treatment, a baseline psychological assessment was performed. 
Subjects were then randomly assigned to receive nicardipine 30mg three 
times daily or sustained release propranolol 160 mg once daily for a 
twelve week period. Observer "blindness" was maintained using a double­
dummy technique. Patients were seen for physical assessments on two 
occasions during the placebo phase and after three, six and twelve weeks 
of treatment. On each occasion, blood pressure was measured by clinic 
staff, with the patient both erect and supine, using a Hawksley random- 
zero sphygmomanometer. Pulse rate and weight were also recorded. 
Compliance was assessed by a tablet count at each visit. Adverse effects 
were elicited by a standard non-directive question. Statistical analysis 
was by the Mann-Whitney U test.
Results
Blood pressure and pulse rate
Again these were not recorded by the author but will be described as they 
are of relevance to interpretation of the psychiatric data.
In the nicardipine group, blood pressure supine was reduced from an
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average of 165.1 (s.d. 18.9) systolic and 102.2 (6.0) diastolic to 151.5 
(15.1) / 88.4 (11.0) (p < 0.01) and from 159.3 (20.0) / 104.1 (4.1) 
standing to 144.5 (15.4) / 88.2 (12.8) (p < 0.01). The propranolol 
patients showed a reduction of supine blood pressure from 177.7 (19.7) / 
107.6 (7.5) to 160.8 (22.6) / 94.1 (12.1) (p < 0.01) and of standing 
pressure from 166.9 (21.2) / 108.3 (9.0) to 150.5 (24.4) / 95.6 (13.4)
(p < 0.01). There were no significant differences between the treatment 
groups at baseline or after twelve weeks of treatment. Propranolol- 
treated patients had a significantly reduced pulse rate from baseline; 
pulse rate was unchanged in the nicardipine patients.
PSYCHOLOGICAL TESTING
The principal results and analyses are described in Table 20.
General Health Questionnaire
There were no significant changes from baseline and no significant 
differences between the treatment groups. Similar findings were 
obtained when the four sub-scales were examined.
Cognitive functioning
a) Wechsler Memory Scale. Significant changes were detected only in the 
digits forward sub-scale with the propranolol group showing an increase 
between weeks 0 and 12. Baseline performance was however lower in the 
propranolol patients in this test. In the logical memory, digits
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backward and associate learning tests there were no significant 
differences between treatments and no changes over the active treatment 
phase.
b) Complex Figure Test
Copy score.There were no significant differences between the two groups 
or changes over time.
Immediate recall. There was a significant deterioration in both the 
nicardipine (p = 0.005) and propranolol (p = 0.038) groups, between 
weeks 0 and 12. Differences between the groups were not significant.
Delayed recall. There was a significant deterioration from baseline in 
the nicardipine group (p = 0.017) and a non-significant decline in the 
scores of the propranolol group.
c) Digit symbol substitution test
There was a significant improvement in the propranolol group between 
weeks 0 and 12 (p = 0.015); there was no change in the nicardipine 
group.
d) Paced Auditory Serial Addition Task.
Average scores on this test improved in both groups; this attained 
statistical significance only in the nicardipine group (p = 0.015).
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Social AdjustMent Schedule
There were no significant changes in scores in the period of active 
treatment and no differences between treatment groups.
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DISCUSSION
STUDY I: PSYCHIATRIC SIDE-EFFECTS OF CAPTOPRIL
This small study provided no evidence for a mood-elevating effect of 
captopril. Indeed symptom scores on the General Health Questionnaire 
were significantly higher during the captopril phase of the trial, 
suggesting decreased psychiatric well-being. There was no change in 
scores on the mania rating scale.
Compliance in the trial was satisfactory as assessed by tablet counts, 
blood pressure reduction, elevation of plasma renin and lowering of 
angiotensin II.
In the absence of an intrinsic mood-elevating effect of captopril, the 
initial observations of increased well-being in captopril-treated 
patients remain unexplained. The most obvious possibility is that the 
increased well-being was due not to captopril but to the absence of the 
adverse physical or psychiatric effects of anti-hypertensive drugs which 
patients had been taking prior to commencing on captopril. The results 
of this study suggested a need to mount detailed studies of the 
psychiatric side-effects of commonly used antihypertensive drugs.
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STUDY II: ATENOLOL AND ENALAPRIL
On psychological testing, the enalapril-treated patients performed 
significantly better than the atenolol-trreated patients on the Digit 
Symbol Substitution Test and the Paced Auditory Serial Addition Task. 
These findings should be interpreted cautiously as a large number of 
statistical comparisons were made and some nominally significant results 
might have been expected to occur by chance even if the drugs were truly 
no different. This seems less likely for the DSST finding which was 
highly significant statistically. Also, both tests measure alertness and 
mental speed and the results are in keeping with each other.
There was no evidence of impairment in tests of verbal and non-verbal 
memory and no differences between treatment groups.
There was no evidence of a decline in psychiatric well-being, as 
assessed by the General Health Questionnaire. There was no evidence of 
impaired social functioning after twelve weeks of treatment.
These results are in keeping with the many studies which have 
demonstrated mild impairment of mental functioning in patients on beta- 
blockers. There are however alternative explanations for the 
differences. The paper by Olajide and Lader (1985) described above 
raised the possibility that enalapril might have an alerting effect and 
this may explain the superior results obtained with enalapril. The 
absolute differences found between the effects of the two drugs were not 
large. In the case of the DSST, the difference was just over 5% of the 
average total score for the enalapril patients. The DSST has been
62
frequently used in the assessment of the cognitive side-effects of 
hypnotic drugs (Peck et al, 1976; Malpas, 1972). There have been several 
single-dose studies which have compared DSST performance twelve hours 
post-dosing in groups of patients taking either active drug and placebo. 
Differences comparable to those of the present study have been found 
when performance on placebo is compared with that on therapeutic doses 
of nitrazepam (Walters and Lader, 1971; Bond and Lader,
1972), flurazepam and butobarbitone (Bond and Lader, 1973). The 
difference in performance between the drugs thus approximates to a 
hypnotic "hangover" effect. Patients on antihypertensive treatment are 
usually on long-term medication in contrast to patients on 
benzodiazepines who should normally be on treatment for no more than a 
few months. The results in the present study are important in that they 
demonstrate differences in performance which are still detectable after 
three months of treatment.
A possible confounding effect arises from the fact that the 
antihypertensive effect of enalapril was superior in this study, which 
raises the possibility that the differences in test performances were 
due to blood pressure differences. The effects of elevated blood 
pressure on mental functioning have been assessed in several studies.
One of the first was carried out by Wilkie and Eisdorfer (1971) who 
examined the effects of hypertension on intellectual functioning in the 
aged. High blood pressure was associated with poor performance on the 
WAIS and a subsequent decline in intellectual powers over a ten year 
follow-up period. No allowance was made for the effects of medication.
In addition, there was evidence of end-organ damage in those with higher
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diastolic pressures. Three studies of carefully treated groups of 
patients with moderate hypertension found no evidence of decline over 
lengthy follow-up periods (Costa and Shock, 1980; Elias et al, 1986; 
Schultz et al, 1986).
Boiler et al (1977) found impaired performance on tests of test of 
reaction time and Digits Forward in a small group of patients with 
diastolic pressures greater than 105 mmHg. There was no evidence of poor 
performance on a large number of other tests, including the DSST. A 
substantial majority of the patients had hypertensive retinopathy which 
raises the possibility that the poor performance may in part have been 
due to occult cerebro-vascular disease and not simply to raised blood 
pressure.
Shapiro et al (1982) looked at cognitive performance in a small group of 
young untreated hypertensives with mild-moderate hypertension. They 
found impaired performance on a number of tests including the DSST. 
Inexplicably, female hypertensives performed less well than males. A 
follow-up study sought to examine the effects of treatment on these 
decrements (Miller et al, 1984). Some evidence of partial restitution of 
function was found although there were several anomalous findings. In 
neither study is the process of diagnosing hypertension described beyond 
the taking of a single blood pressure reading.
Wallace et al (1985) administered a test of verbal memory to a large 
group of elderly subjects. They found that diastolic hypertension was 
associated with impaired verbal memory. Hypertension was diagnosed on 
the basis of blood pressure readings in the course of a single visit.
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No regard was paid to whether subjects were on antihypertensive 
medication and no attempt was made to control for this factor.
The largest comprehensive study of the relationship between blood 
pressure and cognitive performance was carried out as part of the 
Framingham Study (Farmer et al, 1987). A cohort of 2 123 patients aged 
55-89 was examined using a test battery consisting of sub-tests of the 
Wechsler Memory Scale (Logical Memory, Visual Reproduction and Paired 
Associate Learning), sub-tests of the WAIS (Digits Forward, Digits 
Backward and Similarities) and Word Fluency (part of the Multilingual 
Aphasia Examination). Neither blood pressure nor antihypertensive 
treatment was significantly associated with cognitive performance. When 
patients on antihypertensive medication were excluded, there was still 
no relation between blood pressure and cognitive functioning.
In summary, no clear relationship between blood pressure and cognitive 
performance emerges in the studies described, particularly in non- 
elderly populations. In view of the fact that the present group was 
limited to patients under seventy with mild-moderate hypertension, it is 
unlikely that the blood pressure differences between the two treatment 
groups had a significant effect on performance.
It has generally been considered that hydrophilic beta-blockers such as 
atenolol are unlikely to have significant central effects in view of 
their poor ability to traverse the blood-brain barrier (Glaister, 1981). 
Recent research has confirmed that of Salem and McDevitt (1983), cited 
above, in suggesting that atenolol may produce detectable impairment of
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cognitive functioning. Currie et al (1988), in a single dose study in 
healthy volunteers, found decreased alertness after atenolol. Short-term 
memory was impaired by propranolol. Nicholson et al (1988), in a 
similar study, found that body sway was increased and the EEG was 
influenced by both atenolol at doses of 50mg and lOOmg and propranolol 
at doses of 40mg, 80mg and 160mg. Streufert et al (1988) studied the 
performance of fifty hypertensive men on tests of complex cognitive 
functioning after fourteen days on either atenolol or metoprolol. When 
compared to placebo, performance on atenolol was impaired on some of the 
tests whereas performance on metoprolol was superior to placebo. Gengo 
et al (1987) studied the effects of atenolol and metoprolol on the 
Stroop Word Test and CFFF. The subjects were twenty hypertensive men and 
testing was carried out after fourteen days of treatment. Similar 
depression of activity was seen with both drugs. The authors point out 
that the precise site of action of beta-blocker induced sedation is 
unknown and suggest that this may be saturated at low CNS drug 
concentrations.
STUDY III: NICARDIPINE AND PROPRANOLOL
The patients in the propranolol-treated group demonstrated impaired 
performance on tests of non-verbal memory. Again, this is in keeping 
with other research which points to mild memory impairment in subjects 
on beta-blockers. The rise in scores on the DSST between weeks 0 and 12 
was similar in the propranolol patients to that obtained in the atenolol 
group in Study II. The absence of any rise in scores in those on 
nicardipine raises the possibility that performance on this test was
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impaired by nicardipine. Performance on the Complex Figure Test was also 
diminished in the nicardipine patients. In both groups, scores on the 
PASAT improved by the same amount as with the atenolol patients.
As in Study II, there was no evidence of diminished mental well-being or 
impaired social functioning in either treatment group.
As far as the author is aware, there has been no other attempt to assess 
formally the psychological effects of the calcium-channel blockers in 
patients free of diagnosable organic brain disease. The mechanism or 
mechanisms producing impairment of functioning can only be a matter for 
speculation. The potential for the production of "steal" effects, which 
is discussed above, raises the possibility that these drugs may produce 
focal impairment of cerebral blood flow. The possible efficacy of these 
drugs in conditions such as epilepsy and tardive dyskinesia suggests 
that they may have a depressant effect on neuronal functioning which may 
produce mild impairment of mental functioning.
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CONCLUSIONS
In the present studies, enalapril comes out as the drug on which 
patients performed best on the tests which were administered. The 
differences between enalapril and the other drugs were small in 
magnitude and, in the groups studied, were not of sufficient severity to 
produce impaired social adaptation or decreased psychological well­
being. It may that they are of practical significance only in those 
whose occupations require high levels of mental acuity (Ledingham, 1987).
It could be argued that significant impairments of subjective well-being 
or social functioning might exist but that the tests used were 
insufficiently sensitive to detect these. The General Health 
Questionnaire has been very widely used to detect psychiatric morbidity 
in population surveys. It is commonly found in such surveys that between 
fifteen and twenty percent of adults score as having significant 
morbidity (Goldberg, 1978). The questionnaire is therefore capable of 
detecting common-place, low-grade psychiatric morbidity. It is unlikely 
that the questionnaire is missing significant morbidity in the present 
studies. The self-report form of the Social Adjustment Schedule was used 
by Cooper et al (1982), in a study of women undergoing elective 
sterilisation. Statistically significant improvements in scores were 
found when pre-operative and post-operative scores were compared. This 
group of women had no excess of psychiatric symptomatology at any stage 
of the study. The scale was thus able to detect change in a 
psychiatrically "normal” population which was also free of physical 
pathology. It may also be argued that the drugs produced impaired well­
being but that this was counter-balanced by other factors such as
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improvement in psychiatric symptoms as a consequence of recruitment in a 
drug trial as suggested by Mann (1977). The lack of a parallel placebo 
group as dictated by ethical considerations does not allow this factor 
to be excluded. The population differs from that in Mann’s study in that 
most patients were already under treatment for hypertension prior to 
recruitment to the study whereas his population consisted of newly- 
detected hypertensives picked up by population screening. In the case of 
most patients in the studies described here, clinic attendance was not a 
new experience and significant differences between testings would be 
unlikely to be created by the putative psychological benefits of 
enrolment in a drug trial.
The results of the studies reported here are for the most part very 
reassuring and indicate that the antihypertensive drugs investigated do 
not produce detectable impairment in psychiatric well-being or social 
functioning. The studies are free of the methodological problems which 
hampered interpretation of studies such as that of Jachuck et al (1981). 
The results conflict with the findings of the study by Croog et al 
(1986) in which captopril was found to be superior to propranolol and 
methyldopa with regard to subjective well-being. The lack of subjective 
impairment is borne out by the fact that dropout rates in the 
atenolol/enalapril study were low with only four percent of the atenolol 
group and six percent of the enalapril group withdrawing because of 
adverse effects. This contrasts with the Croog et al study where dropout 
rates because of adverse effects were eight percent in the captopril 
patients, thirteen percent in the propranolol patients and twenty 
percent in those on methyldopa. The two populations were not comparable.
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The Croog et al patients were all employed white males whereas the 
present patient groups were not restricted in this way and were therefore 
more representative of the population of hypertensives. This raises the 
possibility that sub-groups of the hypertensive population such as 
working males may be susceptible to subjective adverse effects which are 
not apparent in the population as a whole.
The absence of any effects on memory conflicts with the findings of 
Solomon et al (1983) with regard to their finding of impaired verbal 
memory in patients on propranolol. The design of their study created 
problems of interpretation as described above whereas the study of the 
effects of propranolol described was free of such handicaps. With regard 
to atenolol the present findings are out of keeping with those of 
Lichter et al (1986). Their study used tests of memory not in wide use. 
The cohort of patients was small (twenty-five compared to one 
hundred and thirty-four in the atenolol/enalapril study) and a large 
number of comparisons was made thereby increasing the likelihood of 
positive results occurring by chance.
Beta- blockers may be of positive benefit in certain situations. They 
have been frequently used to improve performance by reduction of 
autonomic response in stressful situations such as undergraduate 
examinations (Brewer,1972), performance on stage by professional 
musicians (James et al,1977; Brantigan et al,1977) and racing-car 
driving (Taggart and Carruthers, 1972). It may be that, in some 
situations or in certain personality types, the beneficial effects of 
beta-blockers may out-weigh the adverse effects (Hartley et al, 1983).
In addition, the beta-blockers have been very widely used over many
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years. Their side-effects and risks are well understood and they are of 
proven efficacy in prevention of the adverse consequences of raised 
blood pressure. The issue of cost of medication must also be taken into 
consideration (Milner and Johnson, 1985). The converting enzyme 
inhibitors are more costly than drugs such as atenolol, which in turn 
costs more than older drugs such as propranolol and bendrofluazide 
(Sahler, 1987).
In addition to the effects of treatment on quality of life, 
investigations have been carried out into the effects of illness 
"labelling". Cross-sectional studies have been published which suggest 
that hypertensive patients have a poorer perception of their health and 
decreased psychlolgical well-being (Milne et al, 1985; Monk, 1981; 
Soghikian, 1981). Such investigations suffer from selection bias in that 
those who feel unwell are more likely to seek medical help and be 
diagnosed as being hypertensive (Wagner and Strogatz, 1984). Two 
prospective studies of this issue found no evidence of significant 
impairment of psychological well-being as a result of diagnosis (Mossey, 
1981; Mann, 1977). Effects of labelling on absenteeism have been found 
to be variable. One study in a large Canadian steel foundry detected 
increased sickness absenteeism following diagnosis of hypertension 
(Haynes et al, 1978). This absenteeism persisted over a four year 
follow-up period and was associated with decreased earnings (Taylor et 
al, 1981; Johnston et al, 1984). Other reports have failed to confirm 
this effect such as that of Alderman et al (1981). There is evidence 
from two studies that adverse social consequences of labelling may be 
largely obviated by close and systematic follow-up (Alderman et al,
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1976; Polk et al, 1984).
Since the planning of the present work, several large reports have 
been published which have attempted to assess the benefits and risks of 
the drug treatment of mild hypertension.
The European Working Party on High Blood Pressure in the Elderly Trial 
was a double-blind, placebo-controlled trial of antihypertensive 
treatment in the over-sixties (European Working Party on High Blood 
Pressure in the Elderly, 1985). The entry criteria were elevated 
diastolic pressure between 90 and 119mmHg and systolic blood pressure 
between 160 and 239mmHg. Eight hundred and forty patients entered the 
trial and were randomly allocated to active treatment of 
hydrochlorothiazide or triamterene or to matching placebo. If blood 
pressure remained elevated methyldopa was added in the active treatment 
group. There was no significant decrease in overall mortality in the 
active treatment group although these patients showed a decrease in 
mortality due to cardiac disease. The incidence of non-fatal cardiac 
events was also less in the actively treated patients as was the 
incidence of minor (i.e. ’’non-terminating") cerebro-vascular events.
The Medical Research Council trial of treatment of mild hypertension was 
mounted to examine whether treatment of men and women aged 35-64 with 
Phase V diastolic blood pressures of 90-109mmHg would be effective in 
reducing the number of strokes and coronary events (Medical Research 
Council Working Party, 1985). The two agents used in the trial were the 
beta-blocker propranolol and the diuretic bendrofluazide. Treatment with 
a second drug was added if blood pressure control was inadequate. The
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trial was carried out in general practice populations and was placebo- 
controlled. A total of 17 354 patients participated. Analysis of the 
results was on an "intention-to-treat" basis. Follow-up was for five 
years. The main benefit experienced by the active treatment group was a 
lowering in the rate of stroke. In the propranolol-treated group, the 
lower incidence of stroke was apparent only in non-smokers. There was no 
difference in the incidence of coronary events and no reduction in 
overall mortality. There was a significant difference between men and 
women with regard to mortality, with men gaining benefit from active 
treatment and women on placebo showing a lower mortality. The rather 
gloomy conclusion of the trial was that if 850 mildly hypertensive 
patients are given active treatment for one year about one stroke will 
be prevented, "an important but an infrequent benefit". This was 
acheived at the expense of subjecting patients to chronic side-effects, 
not all of which were minor.
This conclusion has been challenged by some authorities as being 
excessively cautious (Robertson, 1986; Robertson and Hansson, 1986).
They argue that two factors weakened the power of the trial as initially 
designed. In the first place, it was considered unethical to continue 
patients on placebo if their blood pressures rose above 110 mmHg 
diastolic or 200 mmHg systolic. For this reason, a total of 1011 
patients were withdrawn from placebo and given active treatment. 
Nevertheless, the outcomes in these patients were still analysed as if 
they had remained in the placebo group. It has been argued that these 
patients should have been regarded as having reached a trial end-point 
and been counted accordingly. Secondly, although patients were recruited
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on the basis of having phase V diastolic pressures in the range 90-109 
mmHg, approximately forty percent of patients in the placebo group had 
diastolic pressures lower than 90 mmHg at each annual examination.
Further analysis of the data revealed that patients who were smokers had 
an improved prognosis when treated with bendrofluazide but that no 
benefit could be expected on treatment with propranolol (Medical 
Research Council Working Party, 1988).
The International Prospective Primary Prevention Study in Hypertension 
(IPPPSH) examined the effects of beta-blocker therapy on cardiac 
events and stroke in patients with phase V diastolic pressure betwen 110 
and 115 mm Hg (The IPPPSH Collaborative Group, 1985). Patients were 
randomly allocated double-blind to slow-release oxprenolol or to 
placebo. If blood pressure control was inadequate, the dose of the 
initial medication could be increased or other medication added in 
either the beta-blocker or the placebo group. There was no difference in 
rates of myocardial infarction, cerebrovascular accident and sudden 
death in the two groups. Male non-smokers on oxprenolol experienced half 
as many cardiac events as those on placebo whereas there was a an 
increase in coronary events in smokers on oxprenolol. Interpretation of 
the study is hampered by the fact that over sixty percent of the 
oxprenolol patients and eighty-two percent of the placebo group also 
received a diuretic. It is known that thiazide diuretics can cause 
ventricular ectopy although the significance of this is uncertain 
(Medical Research Council Working Party, 1983). It is possible that the 
cardio-protective effects of oxprenolol were partially out-weighed by 
the use of diuretic. The interaction of smoking and beta-blockade on
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cardiac events may be related to the observation that cigarette smoking 
can have a pressor effect in patients on non-specific beta-blockers such 
as oxprenolol (Trap- Jensen et al, 1979).
The publication of these major, large-scale trials has allowed 
considerable clarification of the indications for antihypertensive drug 
treatment (Wilcox et al,1986; Beevers, 1988). A British Hypertension 
Society Working Party has recommended that drug treatment of 
hypertension is indicated if diastolic blood pressure averages 100 mmHg 
or more over three to four months (Swales et al, 1989). Patients with 
diastolic pressures between 95 and 99 mmHg should have their blood 
pressures checked every three to six months. Intriguing evidence has 
emerged to suggest that there is an optimal range of treated diastolic 
pressure with increased cardiac mortality both below and above this 
range, the so-called J-shaped relation between treated diastolic blood 
pressure and mortality (Cruickshank et al, 1987; Cruickshank, 1988). 
There is increased awareness of the importance of isolated systolic 
hypertension (Dustan, 1989). The potential benefits and limitations 
of non-drug management have also become clearer (Swales, 1987).
The reason for treating hypertension is to diminish the risks of 
hypertension-related morbidity and mortality. Treatment may be for life 
and it is very important that the impact of diagnosis and treatment on 
quality of life is minimal and does not outweigh the expected benefits. 
The existence of even small impairments in mental efficiency may be of 
importance in patients with intellectually demanding occupations.
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It can be argued that all antihypertensive drugs in widespread use 
should be tested fully for effects on "quality of life" as well as for 
antihypertensive efficacy and their ability to prevent disease and 
death. With regard to intellectual functioning, computerised methods of 
testing this will allow more widespread use of such assessments with 
considerable savings in staff time. Detailed delineation of the adverse 
consequences of drug treatment on mental well-being and abilities should 
assist clinicians in choosing the medication most suited to the patient.
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TABLE 1
CAPTOPRIL STUDY
MEAN GHQ TOTAL SCORES (LIKERT)
PATIENT
1
2
3
4
5
6
7
8
PLACEBO
18.0
30.0
22.5
61.5
50.0
68.0
43.0
22.0
CAPTOPRIL
34.5
44.5
33.5
85.0
60.5
71.0
32.5
68.5
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TABLE 2
CAPTOPRIL STUDY
PASAT SCORES
PATIENT
1
2
3
4
5
6
7
8
PLACEBO
55.5
49
118.5
55.5
50 
112
84.5
55.5
CAPTOPRIL
31.5 
36
115.5 
46
87
116.5
104.5
78.5
78
TABLE 3
CAPTOPRIL STUDY
MANIA RATING SCALE SCORES
PATIENT PLACEBO CAPTOPRIL
1 5 0
2 1.75 0.5
3 1.0 1.5
4 3 3
5 5.5 2
6 1 2
7 2 3.5
8 3 1
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TABLE 4 
ATENOLOL VS ENALAPRIL STUDY 
COMPARABILITY OF THE TREATMENT GROUPS AT RANDOMISATION
ATENOLOL (N=76) ENALAPRIL (N=l
Age (years)* 53.0 (1.1) 49.3 (1.3)
Sex (M:F) 45:31 48:38
Weight (kg) 74.2 (1.5) 76.4 (1.6)
Blood pressure (■■Hg) supine*
Systolic 170.8 (1.7) 167.8 (1.5)
Diastolic 98.1 (1.2) 98.2 (1.0)
Pulse rate supine 79.0 (1.4) 80.2 (1.1)
Blood pressure (■■Hg) standing*
Systolic 162.3 (1.7) 158.8 (1.5)
Diastolic 101.6 (1.2) 102.8 (1.0)
Pulse rate standing 84.2 (1.6) 86.7 (1.1)
♦ Values are mean (SEM)
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TABLE 5
MEDIAN RESULTS OF ATENOLOL ENALAPRIL COMPARISONS
ATENOLOL ENALAPRIL
PLACEBO CHANGE PLACEBO CHANGE DIFFERENCE
(95% C.I.s)
General Health 1.0 0.0 0.0 0.0 0.0
Questionnaire (0.0, +1.0)
Social Adjustment 148 0.0 140 -3.0 -3.0
Schedule (-5.0, +7.0)
Complex Figure 33.0 0.0 33.0 0.0 0.0
(Copy) (0.0, +2.0)
Complex Figure 20.0 +1.0 18.5 +1.5 +0.5
(Immediate recall) (-1.0, +2.5)
Complex Figure 18.5 0.0 16.5 +2.0 +2.0
(Delayed recall) (-1.5, +1.5)
Digit forward 7.0 0.0 7.0 0.0 0.0
(0.0)
Digit backward 5.0 0.0 4.5 0.0 0.0
(0.0)
Logical memory 10.0 +1.0 10.0 +0.5 -0.5
(-1.5, +0.5)
Paired associate 14.0 0.0 14.5 -0.5 -0.5
learning (-1.0, +1.0)
DSST 47 +2.0 49 +4.0 +2.0
(+1.0, 4.0)*
PASAT 60.5 +5.5 55.0 +10.0 +4.5
*p < 0.005 **p < 0.05 (0.0, +9.0)**
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TABLE 6
ATENOLOL/ENALAPRIL STUDY
GHQ-60 TOTAL SCORES
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 3.884 3.234
MEDIAN 1.000 1.000
ST. DEV. 5.057 5.881
S.E. MEAN 0.632 0.726
MINIMUM 0.000 0.000
MAXIMUM 21 36
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 3.571 3.500
MEDIAN 0 0
ST. DEV. 6.682 6.524
S.E. MEAN 0.799 0.780
MINIMUM 0 0
MAXIMUM 33 39
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TABLE 7 
ATENOLOL/ENALAPRIL STUDY 
GHQ "CASES”
WEEK ATENOLOL
12
ENALAPRIL
10
4
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TABLE 8 
ATENONOL/ENALAPRIL STUDY 
VALIDATION ASSESSMENT 
SCORES ON GHQ AND CLINICAL INTERVIEW SCHEDULE
PATIENT GHQ SCORE CIS SCORE
1 0 4
2 5 6
3 6 11
4 0 0
5 5 8
6 22 24
7 2 3
8 9 4
9 1 8
10 0 2
11 0 12
12 1 5
13 0 5
14 0 12
15 5 6
16 0 1
17 1 5
18 18 23
19 3 6
20 1 0
21 1 6
22 0 11
23 0 0
24 0 1
25 0 0
26 0 2
27 8 15
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TABLE 9
ATENOLOL/ENALAPRIL STUDY
DIGITS FORWARD
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 6.672 6.703
MEDIAN 7 7
ST. DEV. 1.16 1.366
S.E. MEAN 0.145 0.171
MINIMUM 4 0
MAXIMUM 8 8
ENALAPRIL GROUP
PLACEBO ENALAPRIL
MEAN 6.886 7.114
MEDIAN 7 7
ST. DEV. 1.036 0.979
S.E. MEAN 0.124 0.117
MINIMUM 4 4
MAXIMUM 8 8
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TABLE 10
ATENOLOL/ENALAPRIL STUDY
DIGITS BACKWARD
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 4.992 4.953
MEDIAN 5 5
ST. DEV. 1.338 1.255
S.E. MEAN 0.167 0.157
MINIMUM 2 2
MAXIMUM 7 7
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 4.771 5.014
MEDIAN 4.5 4.5
ST. DEV. 1.233 1.236
S.E. MEAN 0.147 0.148
MINIMUM 2 2
MAXIMUM 7 7
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TABLE 11 
ATENOLOL/ENALAPRIL STUDY 
PAIRED ASSOCIATE LEARNING
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 13.992 13.787
MEDIAN 14.0 14,0
ST. DEV. 3.965 3.658
S.E. MEAN 0.496 0.457
MINIMUM 5.5 5.5
MAXIMUM 21.0 21.0
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 14.614 14.643
MEDIAN 14.5 14.0
ST. DEV. 3.489 3.655
S.E. MEAN 0.417 0.437
MINIMUM 7.0 6.0
MAXIMUM 21.0 21.0
87
TABLE 12 
ATENOLOL/ENALAPRIL STUDY 
LOGICAL MEMORY
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 9.881 10.797
MEDIAN 10 11
ST. DEV. 3.688 3.783
S.E. MEAN 0.461 0.473
MINIMUM 1.0 0
MAXIMUM 18.5 18.5
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 10.257 10.751
MEDIAN 10 10.5
ST. DEV. 3.498 3.504
S.E. MEAN 0.418 0.419
MINIMUM 4.5 1.0
MAXIMUM 22.0 18.0
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TABLE 13 
ATENOLOL/ENALAPRIL STUDY 
COMPLEX FIGURE TEST -COPY
ATENOLOL GROUP (N=63)
PLACEBO ATENOLOL
MEAN 32.25 32.22
MEDIAN 33 33
ST.DEV. 4.046 4.007
S.E. MEAN 0.510 0.515
MINIMUM 16.0 16.5
MAXIMUM 36.0 36.0
ENALAPRIL GROUP (N=69)
PLACEBO ENALAPRIL
MEAN 31.44 31.88
MEDIAN 33 33
ST. DEV. 4.323 5.054
S.E. MEAN 0.520 0.608
MINIMUM 14.5 14.0
MAXIMUM 36.0 36.0
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ATENOLOL/ENALAPRIL STUDY 
COMPLEX FIGURE TEST -IMMEDIATE RECALL
TABLE 14
 
ATENOLOL GROUP (N=62)
PLACEBO ATENOLOL
MEAN 19.75 20.90
MEDIAN 20.0 21.5
ST. DEV. 7.404 7.381
S.E. MEAN 0.940 0.937
MINIMUM 2.0 3.0
MAXIMUM 32.0 34.0
ENALAPRIL GROUP (N=69)
PLACEBO ENALAPRIL
MEAN 17.94 19.80
MEDIAN 18.5 20.0
ST. DEV. 6.699 7.244
S.E. MEAN 0.807 0.872
MINIMUM 4.5 0.0
MAXIMUM 31.0 32.0
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TABLE 15
ATENOLOL/ENALAPRIL STUDY
COMPLEX FIGURE TEST -DELAYED RECALL
ATENOLOL GROUP (N=62)
PLACEBO ATENOLOL
MEAN 17.73 19.61
MEDIAN 18.5 18.5
ST.DEV. 9.05 8.15
S.E. MEAN 1.16 1.04
MINIMUM 0.0 0.0
MAXIMUM 32.0 34.0
ENALAPRIL GROUP (N=69)
PLACEBO ENALAPRII
MEAN 16.06 18.49
MEDIAN 16.5 18.5
ST. DEV. 7.536 7.738
S.E. MEAN 0.942 0.967
MINIMUM 0.0 0.0
MAXIMUM 31.0 31.0
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TABLE 16
ATENOLOL/ENALAPRIL STUDY
DIGIT SYMBOL SUBSTITUTION
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 47.58 49.59
MEDIAN 47 49
ST. DEV. 13.16 14.03
S.E. MEAN 1.64 1.75
MINIMUM 16 14
MAXIMUM 82 85
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 48.41 52.50
MEDIAN 49 53
ST. DEV. 12.18 12.55
S.E. MEAN 1.46 1.50
MINIMUM 19 23
MAXIMUM 75 79
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TABLE 17 
ATENOLOL/ENALAPRIL STUDY 
PACED AUDITORY SERIAL ADDITION TASK
ATENOLOL GROUP (N=60)
PLACEBO ATENOLOL
MEAN 60.98 66.60
MEDIAN 60.5 66
ST. DEV. 22.11 26.43
S.E. MEAN 2.72 3.41
MINIMUM 6 9
MAXIMUM 109 114
ENALAPRIL GROUP (N=63)
PLACEBO ENALAPRIL
MEAN 58.58 68.90
MEDIAN 55 65
ST. DEV. 22.60 26.02
S.E. MEAN 2.65 3.28
MINIMUM 9 6
MAXIMUM 105 117
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TABLE 18
ATENOLOL/ENALAPRIL STUDY
SOCIAL ADJUSTMENT SCALE -TOTAL SCORES
ATENOLOL GROUP (N=64)
PLACEBO ATENOLOL
MEAN 155.20 150.05
MEDIAN 148 148
ST. DEV. 31.44 29.44
S.E. MEAN 3.93 3.68
MINIMUM 111 105
MAXIMUM 236 250
ENALAPRIL GROUP (N=70)
PLACEBO ENALAPRIL
MEAN 145.73 142.80
MEDIAN 140 137
ST. DEV. 29.45 26.91
S.E. MEAN 3.52 3.22
MINIMUM 105 108
MAXIMUM 241 239
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TABLE 19 
NICARDIPINE/PROPRANOLOL TRIAL 
DEMOGRAPHIC CHARACTERISTICS
NICARDIPINE PROPRANOLOL
AGE (S.D.) 52.5 (11.9) 55.9 (6.6)
SEX
Male 8 8
Female 7 7
EDUCATION
Special school 0 1
Secondary school
to age 15 10 12
Secondary school
to age 18 4 1
Higher education 1 1
OCCUPATION/SOCIAL CLASS
I 1 0
II 1 1
III (i) 1 2
III (ii) 1 0
IV 4 1
V 1 0
Unemployed/retired 6 11
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TABLE 20
NICARDIPINE AND PROPRANOLOL STUDY 
RESULTS AND COMPARISONS
WEEK NICARDIPINE PROPRANOLOL
GHQ-60 (Total scores and ranges)
0 5.9 (0-19) 11.1 (0-49)
12 10.1 (0-48) 10.9 (0-50)
Social Adjustment (Total scores and s.d.)
0 1.59 (0.43) 1.69 (0.35)
12 1.68 (0.63) 1.66 (0.33)
Logical memory
0 9.8 (3.2) 9.8 (3.0)
12 9.8 (3.9) 9.6 (3.3)
Digits forward
0 6.9 (1.0) 6.1 (1.5)
12 6.8 (1.1) 6.8 (1.2)*
Digits backward
0 4.8 (1.4) 4.6 (1.4)
12 5.1 (1.3) 4.8 (1.4)
Associate learning
0 13.3 (3.2) 12.2. (4.9)
12 13.9 (5.1) 11.7 (3.9)
♦Significant increase Week 0-12 (p=0.033)
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TABLE 20 (continued)
DSST
0 43.0 (16.2) 44.3 (13.1)
12 42.9 (14.6) 47.9 (13.6)*
CFT (Copy)
0 29.6 (5.6) 30.0 (3.4)
12 27.4 (7.9) 30.1 (5.4)
CFT (Immediate recall)
0 19.1 (8.4) 19.2 (6.0)
12 14.4 (9.2)** 16.3 (7.7)***
CFT (Delayed recall)
0 17.7 (8.5) 17.6 (5.9)
12 14.3 (9.0)+ 16.0 (7.6)
PASAT
0 64.0 (18.4) 60.8 (25.2)
12 70.1 (24.9)++ 66.1 (28.0)
♦Significant increase Week 0-12 (p=0.015)
**Significant decrease Week 0-12 (p=0.005)
***Significant decrease Week 0-12 (p=0.038)
+Significant decrease Week 0-12 (p=0.017)
++Signif icant increase Week 0-12 (p=0.038)
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GENERAL HEALTH 
QUESTIONNAIRE
Please read this carefully:
We should like to know if you have had any medical complaints, and how your health has been in 
general, over the past few weeks. Please answer ALL the questions on the following pages simply by under­
lining the answer which you diink most nearly applies to you. Remember that we want to know about 
present and recent complaints, not those that you had in the past.
It is important that you try to answer ALL the questions.
Thank you very much for your co-operation.
HAVE YOU RECENTLY:
1 — been feeling perfectly well and Better Same Worse Much worse
in good health? than usual as usual than usual than usual
2 __ been feeling in need of a good tonic? Not No more Rather more Much more
at all than usual than usual than usual
3 been feeling run down and out of sorts? Not No more Rather more Much more
at all than usual than usual than usual
4 — hilt that you are ill? Not No more Rather more Much more
at all than usual than usual than usual
5 __ been getting any pains in your head? Not No more Rather more Much more
at all than usual than usual than usual
6 _ _ been getting a feeling of tightness or Not No more Rather more Much more
pressure in your head? at all than usual than usual than usual
7 been able to concentrate on whatever Better Same Less Much less
you're doing? than usual as usual than usual than usual
8 been afraid that you were going to Not No more Rather more Much more
collapse in a public place? at all than usual than usual than usual
9 — been having hot or cold spells? Not No more Rather more Much more
at all than usual than usual than usual
10 — been perspiring (sweating) a lot? Not No more Rather more Much more
at all than usual than usual than usual
11 _ found yourself waking early and Not No more Rather more Much more
unable to get back to sleep? at all than usual than usual than usual
12 __ been getting up feeling your sleep Not No more Rather more Much more
hasn't refreshed you? at all than usual than usual than usual
13 been feeling too tired and exhausted Not No more Rather more Much more
even to eat? at all than usual than usual than usual
PLEASE TURN OVER
HAVE YOU RECENTLY:
14 -  lost much sleep over worry? Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
15 -  been feeling mentally alert and wide 
awake?
Better 
than usual
, Same 
as usual
Less alert 
than usual
Much less
alert
16 — been feeling full of energy? Better 
than usual
Same 
as usual
Less energy 
than usual
Much less 
energetic
17 — had difficulty in getting off to sleep? Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
18 -  had difficulty in staying alseep once 
you are off?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
19 — been having frightening or unpleasant 
dreams?
Not
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
20 — been having restless, disturbed nights? Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
21 — been managing to keep yourself busy 
and occupied?
More so 
than usual
Same 
as usual
Rather less 
than usual
Much less 
than usual
22 — been taking longer over the things 
you do?
Quicker 
than usual
Same 
as usual
Longer 
than usual
Much longer
than usual
23 — tended to lose interest in your 
ordinary activities?
Not 
at all
No more 
than usual
Rather more 
than usual
Much more 
than usual
24 — been losing interest in your personal 
appearance?
Not 
at all
Wo more 
than usual
Rather more 
than usual
Much more 
than usual
25 — been taking less trouble with your 
clothes?
More trouble 
than usual
About same 
as usual
Less trouble 
than usual
Much less 
trouble
26 -  been getting out of die house as 
much as usual?
More
than usual
Same 
as usual
Less
than usual
Much less 
than usual
27 — been managing as well as most people 
would in your shoes?
Better 
than most
About 
the same
Rather 
less well
Much 
less well
28 — felt on the whole you were doing 
things well?
Better
than usual
About 
the same
Less well 
than usual
Much 
less well
29 -  been late getting to work, or getting 
started on your housework?
Not 
at alt
No later 
than usual
Rather later
than usual
Much later 
than usual
30 — been satisfied with the way you've 
carried out your task?
More
satisfied
About same 
as usual
Less satisfied 
than usual
Much less
satisfied
31 -  been able to feel warmth and 
affection for those near to you?
Better 
than usual
About same 
as usual
Less well 
than usual
Much less
well
32 — been finding it easy to get on with 
other people?
Better 
than usual
About same 
as usual
Less well 
than usual
Much less 
well
33 -  spent much time chatting with 
people?
More time 
than usual
About same 
as usual
Less
than usual
Much less 
than usual
GO ON TO THE NEXT PAGE
HAVE YOU RECENTLY:
34 - kept feeling afraid to say anything Not No more Rather more Much more
to people in case you made a fool at all than usual than usual than usual
of yourself?
35 — felt that you are playing a useful More so Same Less useful Much less
part in things? than usual as usual than usual useful
36 — felt capable of making decisions More so Same Less so Much less
about things? than usual as usual than usual capable
37 — felt you’re just not able to make a Not No more Rather more Much more
start on anything? at all than usual than usual than usual
38 — felt yourself dreading everything that Not No more Rather more Much more
you have to do? at all than usual than usual than usual
39 — felt constantly under strain? Not No more Rather more Much more
at all than usual than usual than usual
40 — felt you couldn't overcome your Not No more Rather more Much more
difficulties? at all than usual than usual than usual
41 _ been finding life a struggle all die time? Not No more Rather more Much more
at all than usual than usual than usual
42 been able to enjoy your normal More so Same Less so Much less
day-to-day activities? than usual as usual than usual than usual
43 — been taking things hard? Not No more Rather more Much more
at all than usual than usual than usual
44 — been getting edgy and Not No more Rather more Much more
bad-tempered? at all than usual than usual than usual
45 — been getting scared or panicky for Not No more Rather more Much more
no good reason? at all than usual than usual than usual
46 — been able to face up to your More so Same Less able Much less
problems? than usual as usual than usual able
47 — found everything getting on top Not No more Rather more Much more
of you? at all than usual than usual than usual
48 — had the feeling that people were Not No more Rather more Much more
looking at you? at all than usual than usual than usual
49 __ been feeling unhappy and depressed? Not No more Rather more Much more
at all than usual than usual than usual
50 — been losing confidence in yourself? Not No more Rather more Much more
at all than usual than usual than usual
51 — been thinking of yourself as a Not No more Rather more Much more
worthless person? at all than usual than usual than usual
52 — felt that life is entirely hopeless? Not No more Rather more Much more
at all than usual than usual than usual
53 __ been feeling hopeful about your own More so About same Less so Much less
future? than usual as usual than usual hopeful
PLEASE TURN OVER
HAVE YOU RECENTLY:
54 -  been feeling reasonably happy, all More so About same Less so Much less
things considered? than usual as usual than usual than usual
55 -  been feeling nervous and strung-up Not No more Rather more Much more
all the time? at all than usual than usual than usual
56 -  felt that life isn't worth living? Not No more Rather more Much more
at all than usual than usual than usual
57 -  thought of the possibility that you Definitely I don't Has crossed Definitely
might make away with yourself? not think so my mind have
58 — found at times you couldn't do Not No more Rather more Much more
anything because your nerves were 
too bad?
at all than usual than usual than usual
59 -  found yourself wishing you were dead Not No more Rather more Much more
and away from it all? at all than usual than usual than usual
60 -  found that the idea of taking your own Definitely I don't Has crossed Definitely
life kept coming into your mind? not think so my mind has
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Signature of Interviewer: 
NOTES:
Date of Interview
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GENERAL PRACTITIONER’S NOTES ON INDEX CONSULTATION
HISTORY OF PRESENT CONDITION
I understand you saw Dr . . . . . . . . . . . . . .  on  ...........
Would you mind telling me about that?
(give brief history of present complaint, including samples of 
patient’s account verbatim.)
Try to elicit a) date of onset (as near as possible)
b) mode of onset (whether sudden, gradual, etc)
(For working patients) Have you had to take any time off work
because of this trouble (i.e. in the past 3 months)?
(For all others, Has this trouble interfered with any of your normal
incl. housewives) activities (i.e. in the past 3 months)?
IF YES, ascertain details
-3-
GENERAL MEDICAL HISTORY
Now I ’d like to ask you about your previous health. Have you had any serious 
i11 nesses?
What about operations?
(check the following)
Chronic chest condition (e.g. bronchitis, asthma)?
High blood pressure?
Heart trouble?
Stomach or bowel trouble (e.g. stomach ulcers, gastritis)
Jaundice?
Kidney or bladder disease?
Diabetes?
Any serious skin trouble?
Arthritis (stiffness, pain in the joints)?
Any kind of growth or tumour?
Anything else?
Do you suffer from any kind of ill-health now (apart from what you came to see 
Dr . . . . . . . . . . . . . .  about)?
Have you ever had a nervous breakdown, or suffered from bad nerves?
Were you ever a patient in a hospital for nerves (Mental Hospital)?
Did anyone in your family suffer from nervous trouble?
- or have treatment in a hospital for nerves (Mental Hospital)?
-4-
How long has Dr . ..................  been your doctor now?
(If a new episode)
When was the last time you saw him before this recent trouble?
What was that for?
(If not a new episode)
How long have you been seeing him for this trouble?
During the past year, have you been under any other doctor?
- have you been in hospital or attended hospital?
ADDITIONAL NOTES ON MEDICAL HISTORY
(Including any special points from patient’s medical notes)
ANY SPECIAL COMMENTS ON MEDICAL HISTORY BY PATIENTS’S G.P.
-5-
Have you noticed anything else wrong with your health apart from the things 
that you’ve already told me?
(Anything else?)
In the past week, have you been troubled with a) headache
b) indigestion
c) backache
If the rater suspects that psychological mechanisms may be implicated in any 
of the somatic symptoms described, elicit more details as follows:-
How long have you had this trouble?
Does it seem to get worse when your nerves are bad?
How much does it upset you?
How often have you had it in this past week?
SOMATIC SYMPTOMS 4 3 2 1 0
ALL PATIENTS:- Are you at all worried about your health at the moment?
Do you find yourself thinking a lot about your health, or about the workings of 
any part of your body?
Do you every worry about having cancer? or heart disease?
(The following Part 2 rating may be made at this point if the rater wishes) 
EXCESSIVE CONCERN WITH BODILY FUNCTIONS 4 3 2 1 0
Have you noticed that you get tired easily?
Or tht you seem to be lacking in energy?
If the patient’s replies indicate excessive fatigue or lethargy, go on as 
follows:-
How long have you noticed this?
Do you feel tired the whole time, or just now and then?
What sort of things do you find most tiring?
Do you feel completely tired out in the evening?
How has it been this past week?
Has it stopped you from doing anything you’ve wanted to do?
FATIGUE 4 3 2 1 0
-7-
What about your sleep?
(If reply indicates difficulties, ask for details):- 
Do you have difficulty dropping off?
Are you restless at night?
Do you wake early?
Have you lost any sleep in the past week?
If the patient’s replies indicate loss of sleep in the past week, 
go on as follows:-
How long have you had this trouble?
Have you any idea why you can’t sleep?
How many nights in the past week have you lost sleep?
How many hours sleep do you think that you miss on a bad night?
SLEEP DISTURBANCE 4 3 2 1 0
ALL PATIENTS:-
Do you take any sleeping pills?
If YES, o on to ask:-
Do you get them from your doctor?
Do you know what they are called?
Do you take them every night, or just now and again?
How many have you had in the past week?
HYPNOTICS 2 1 0
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Do you find that you are easily upset or irritable with those around you?
If the patient’s reply indicates irritability, go on as follows:- 
How long have you been like this?
Are you like it all the time or just occasionally?
What sort of things upset you?
How has it been in the past week?
Have you had any rows with anyone in this past week?
Are there still any hard feelings?
IRRITABILITY 4 3 2 1 0
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Do you find it difficult to concentrate? 
Do you get muddled or forgetful?
If replies indicate impairment, go on as follows:- 
How long have you noticed this trouble?
Do you notice it all the time or just now and then?
Has it caused any difficulty at home?
at work?
Can you concentrate on a newspaper or on a play on T.V.?
How bad has it been in this past week?
Has it stopped you from doing anything?
How many of your activities are affected?
LACK OF CONCENTRATION 4 3 2 1 0
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How have you been feeling in your spirits in the past week? 
Have you had spells of feeling sad or miserable?
If the patient’s replies indicate despondency or sadness, go on as follows:- 
Have you felt low the whole time or just occasionally?
Does it seem connected with anything that happens?
How bad does it get?
Do you ever get weepy?
Can you snap out of it?
Do you sometimes feel hopeless?
Have you felt like making an end to it all?
DEPRESSION 4 3 2 1 0
If indicated, ask the following questions for the Part 2 rating of depressive 
thoughts
Do you every blame yourself for being like this?
Do you ever find yourself feeling guilty?
Do you sometimes feel inferior to other people?
How do you feel about the future?
-11-
Would you say that you are a highly-strung or nervous person?
Do you ever find that you get anxious or frightened for no good reason? 
Do you worry a lot about things?
If the patient’s replies indicate anxiety and worrying, go on and ask more:- 
What sort of things do you chiefly worry about?
Have you always been like this, or is it something that has only started
recently?
Do you worry all the time, or only now and then?
Do you find yourself worrying more than you need about little things?
Have you been upset by worries in the past week?
ANXIETY 4 3 2 1 0
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Are there any special things or situations that you find frightening or 
upsetting?
What about being alone in the house?
- going out by yourself?
- travelling on buses or trains?
- animals? insects? heights? the dark?
If patient’s replies indicate any phobias, go on to elicit details, viz:- 
How severe is this?
Do you get it all the time or just now and again?
How bad has it been in this past week?
Do you have to go out of your way to avoid 
or alter your usual activities in any way?
PHOBIAS 4 3 2 1 0
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Do you ever find that you have to do things over and over to make sure that 
you’ve done them right?
Or that you keep having unwelcome thoughts that you can’t get rid of? 
(If patient asks what is meant, Well any sort of unpleasant thought 
that comes into your mind against your will).
Do you find it hard to make decisions?
If the patient’s replies indicate possible obsessions or compulsions, ask
appropriate questions from the following:-
(CHECKING)
How many times do you find yourself checking your work?
Do you check it even thought you know that it’s right really?
Are there any other things that you find yourself having to do 
a number of times?
UNWELCOME THOUGHTS
Can you describe them to me?
DIFFICULTY WITH DECISIONS
Is this something that you’ve always had or is it something new?
Is it just over important issues or does it affect trivialities as well?
ALL PHENOMENA
Do you try and struggle against it?
Is it very distressing?
Does it take up much of your time?
How bad has it been in this past week?
OBSESSIONS 4 3 2 1 0
-14-
Do you ever get the feeling that you’re not really there. Or that 
everything around you seems unreal?
If patient’s replies indicate possible depersonalisation, go on to elicit 
details, viz:-
Can you describe the feeling?
Do you find it unpleasant or frightening?
Do you get it every day or just now and again?
How long does it last when you get it?
How bad has it been just lately (e.g. in this past week)?
DEPERSONALISATION 4 3 2 1 0
Is there anything else to do with your health that you think might be 
important?
- or anything I haven’t asked you about?
FAMILY PSYCHIATRIC HISTORY
BRIEF PERSONAL AND SOCIAL HISTORY
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PART TWO RATINGS
Evidence for 
Disturbance
Psychiatric 
Noted at Interview
Name of Rating: Reason for Morbid Rating: Rating Assigned
SLOW, lacking
spontaneity
4 3 2 1 0
SUSPICIOUS,
defensive
4 3 2 1 0
HISTRIONIC 4 3 2 1 0
DEPRESSED 4 3 2 1 0
ANXIOUS, TENSE 
AGITATED
4 3 2 1 0
ELATED, euphoric 4 3 2 1 0
FLATTENED,
INCONGRUOUS
4 3 2 1 0
DELUSIONS, 
Misinterpretations 
THOUGHT DISORDER
4 3 2 1 0
HALLUCINATIONS 4 3 2 1 0
INTELLECTUAL
IMPAIRMENT
4 3 2 1 0
The following ratings may already have been made:-
EXCESSIVE CONCERN 
with BODILY FUNCTIONS
4 3 2 1 0
DEPRESSIVE THOUGHTS 4 3 2 1 0
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Interviewer* s notes
Summary and Formulation
Assessment of the Reliability of the Information
GOOD / FAIR / POOR
I.C.D. DIAGNOSIS
Principal Diagnosis 
Ancillary Diagnosis
D.S.M. DIAGNOSIS
OVERALL SEVERITY RATING
4 3 2 1 0
SOCIAL ADJUSTMENT - SELF REPORT QUESTIONNAIRE
I am interested in finding out how you have been doing in the last two weeks.
We would like you to answer some questions about your work, your spare time and 
your family life. There are no right or wrong answers to these questions. 
Please tick the answer that best describes how you have been in the last 
two weeks.
WORK OUTSIDE THE HOME
Please tick the situation that best describes you. 
I am 1) .. a worker for pay
2) .. a housewife
3) .. a student
4) .. retired
5) .. unemployed
usually work for more than
1) YES 2) NO
Did you work any hours for pay in the last two weeks?
1)   YES 2) __  NO
Tick the answer that best describes how you have been in the last two weeks.
1. How many days did you miss from work in the last two weeks?
1 )
2)
3)
4)
5)
6)
No days missed 
One day.
I missed about one week
I missed more than a week but managed to work at least one day, 
I did not work any days.
I was on holiday all of the last two weeks.
If you have not worked any days in the last two weeks, please go on to 
Question 7.
2. Have you been able to do your work in the last two weeks?
1 )
2)
3)
4)
5)
I did my work very well.
I did my work well but had some minor problems.
I needed help with work and did not do well about half of the
time.
I did my work poorly most of the time.
I did my work poorly all the time.
3. Have you been ashamed about how you did your work in the last two weeks.
1)-- --  I never felt ashamed.
2) __  Once or twice I felt a little ashamed.
3) __  About half of the time I felt ashamed.
4) __  I felt ashamed most of the time.
5) __  I felt ashamed all of the time.
4. Have you had any arguments with people at work in the last two weeks?
1) .... I had no arguments and got along very well.
2)   I usually get along well but had minor arguments.
3)   I had more than one argument.
4)   I had many arguments.
5)   I was consistently involved in arguments.
5. Have you felt upset, worried or uncomfortable while doing your work 
during the last two weeks.
1)__ __  I never felt upset.
2) __  Once or twice I felt upset.
3) __  Half of the time I felt upset.
4) __  I felt upset most of the time.
5) __  I felt upset all of the time.
6. Have you found your work interesting in these last two weeks.
1)__ __  My work was almost always interesting.
2) __  Once or twice my work was not interesting.
3) __  Half of the time my work was uninteresting.
4) __  Most of the time my work was uninteresting.
5) __  My work was always uninteresting.
WORK AT HOME - HOUSEWIVES ANSWER QUESTIONS 7 - 1 2 . OTHERWISE. GO TO QUESTION 13.
7. How many days did you do some housework in the last two weeks?
1) __  Every day.
2) __  I did housework almost every day.
3) __  I did housework about half of the time.
4) __  I usually did not do housework.
5) __  I was completely unable to do housework.
6) __  I was away from home all of the last two weeks.
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During the last two weeks, have you kept up with your housework, 
includes, cooking, cleaning, laundry, shopping and messages.
This
1)
2 )
3)
4)
5)
I did my work wel1.
I did my work well but had some minor problems.
I needed help with my work and did not do it well about
half the time.
I did my work poorly most of the time.
I did my work poorly all of the time.
Have you been ashamed about how you did your housework during the last 
two weeks?
1 )
2)
3)
4)
5)
I never felt ashamed.
Once or twice I felt a little ashamed, 
About half the time I felt ashamed.
I felt ashamed most of the time.
I felt ashamed all of the time.
10. Have you had any arguments with salespeople, tradesmen or neighbours in 
the last two weeks.
1)
2)
3)
4)
5)
I had no arguments and got along very well.
I usually got along well but had minor arguments, 
I had more than one argument.
I had many arguments.
I was constantly involved in arguments.
11. Have you felt upset while doing your housework during the last two weeks,
1)
2)
3)
4)
5)
I never felt upset.
Once or twice I felt upset. 
Half the time I felt upset.
I felt upset most of the time, 
I felt upset all the time.
12. Have you found your housework interesting in these last two weeks?
1)
2)
3)
4)
5)
My work was almost always interesting.
Once or twice my work was not interesting. 
Half the time my work was uninteresting. 
Most of the time my work was uninteresting. 
My work was always uninteresting.
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FOR STUDENTS
ANSWER QUESTIONS 13 - 18 if you attend school, college or University for 
half of your time or more, if not please go on to QUESTION 19.
What best describes your study programme? (choose one)
1)   Full time.
2) __  3/4 time.
3) __  Half time.
Tick the answer that best describes how you have been in the last two weeks.
13. How many days of classes did you miss in the last two weeks?
1)   No days missed
2)   A few days missed.
3)   I missed about half the time.
4)   I missed more than half the time but did attend at least one day.
5)   I did not go to classes at all.
6)   I was on holiday during the last two weeks.
14. Have you been able to keep up with your class work in the last two weeks?
1)   I did my work very well.
2)   I did my work well but had minor problems.
3)   I needed help with my work and did not do well about half the
time.
4)   I did my work poorly most of the time.
5)   I did my work poorly all of the time.
15. During the last two weeks, have you been ashamed of the way you did your 
school/college/University work?
1)__ __  I never felt ashamed.
2)__ __  Once or twice I felt ashamed.
3)__ __  About half the time I felt ashamed.
4)__ __  I felt ashamed most of the time.
5)__ __  I felt ashamed all of the time.
16. Have you had any arguments with people at school/college/University in the 
last two weeks?
1) .. .. I had no arguments and got along very well.
2) .. .. I usually got along well but I had minor arguments.
3) .. .. I had more than one argument.
4) .. .. I had many arguments.
5) .. .. I was constantly involved in arguments.
6) .. Not applicable; I did not attend school/college/University.
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17. Have you felt upset at school/college/University during the last two weeks?
1)-- --  I never felt upset.
2) --  Once or twice I felt upset.
3) __  Half the time I felt upset.
4) __  I felt upset most of the time.
5) __  I felt upset all of the time.
6) __  Not applicable; I did not attend school/college/University.
18. Have you found school/college/University work interesting these last two 
weeks?
1)__ __  My work was almost always interesting.
2) __  Once or twice my work was not interesting.
3) __  Half the time my work was uninteresting.
4) __  Most of the time my work was uninteresting.
5) .... My work was always uninteresting.
SPARE TIME - EVERYONE PLEASE ANSWER QUESTIONS 1 9 - 2 7 .
Tick the answer that best describes how you have been in the last two weeks.
19. How many friends have you seen or spoken to on the telephone in the last 
two weeks?
1)__ __  Nine or more friends.
2) __  Five to eight friends.
3) __  Two to four friends.
4) __  One friend.
5) __  No friends.
20. Have you been able to talk about your feelings and problems with at least 
one friend during the last two weeks?
1)__ __  I can usually talk about my innermost feelings.
2) __  I usually can talk about my feelings.
3) __  About half of the time I felt able to talk about my feelings.
4) __  I usually was not able to talk about my feelings.
5) .... I was never able to talk about my feelings.
6) __  Not applicable; I have no friends.
21. How many times in the last two weeks have you gone out socially with other 
people? For example, visited friends, gone to the cinema, football, 
church, restaurants, invited friends to your home?
1) .. .. More than 3 times.
2) .. .. Three times.
3) .. .. Twice.
4) .. .. Once.
5) .. .. None.
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22. How much time have you spent on hobbies or spare time interests during 
the last two weeks? For example, football, sewing, gardening, sport 
and reading?
1)   I spent most of my spare time on hobbies almost every day.
2)   I spent some spare time on hobbies some of the days.
3)   I spent a little spare time on hobbies.
4)   I usually did not spend any time on hobbies but I did watch T.V.
5) .... I did not spend any spare time on hobbies or watching T.V.
23. Have you had open arguments with your friends in the last two weeks?
1) .. .. I had no arguments and got along very well.
2) .. .. I usually got along well but had minor arguments.
3) .. .. I had more than one argument.
4) .. . . I had many arguments.
5) .. .. I was constantly involved in arguments.
6) .. Not applicable; I have no friends.
24. If your feelings were hurt or offended by a friend during the last two 
weeks, how badly did you take it?
1)__ __  It did not affect me or it did not happen.
2)__ __  I got over it in a few hours.
3) .... I got over it in a few days.
4) __  I got over it in a week.
5) __  It will take me months to recover.
6) __  Not applicable; I have no friends.
25. Have you felt shy or uncomfortable with people in the last two weeks?
1)__ __  I always felt comfortable.
2) .... Sometimes I felt uncomfortable but could relax after a while.
3)__ __  About half the time I felt uncomfortable.
4) __  I usually felt uncomfortable.
5)__ __  I always felt uncomfortable.
6)__ __  Not applicable; I was never with people.
26. Have you felt lonely and wished for more friends during the last two weeks?
1)__ __  I have not felt lonely.
2)__ __  I have felt lonely a few times.
3)__ __  About half the time I felt lonely.
4) __  I usually felt lonely.
5)__ __  i always felt lonely and wished I had more friends.
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27. Have you felt bored in your spare time during the last two weeks?
1) .. I never felt bored.
2) .. I usually did not feel bored.
3) .. .. About half the time I felt bored
4) .. .. Most of the time I felt bored.
5) .. I was constantly bored.
Are you a Single, Separated, or Divorced Person not living with a person of the 
opposite sex; please answer below -
1) --  YES If YES, answer questions 28 and 29.
2) .... NO If NO, please go on to question 30.
28. How many times have you gone out socially with a member of the opposite 
sex during the last two weeks?
1)__ __  More than 3 times.
2)__ __  Three times.
3) __  Twice.
4) .... Once.
5) __  Never.
29. Have you been interested in going out socially with members of the opposite 
sex during the last two weeks. If you have not gone out with a member of 
the opposite sex would you have liked to?
1)__ __  I was always interested in going out with a member of the opposite
sex.
2) __  Most of the time I was interested.
3) __  About half of the time I was interested.
4) __  Most of the time I was not interested.
5) __  I was completely uninterested.
FAMILY
Answer questions 30 - 37 about your parents, brothers, sisters, in-laws, 
and children not living at home. Have you been in contact with any of them in 
the last two weeks?
1) __  YES. If YES, please answer questions 3 0 - 3 7 .
2) __  NO. If NO, please go on to question 36.
-8-
30. Have you had open arguments with your relatives in the last two weeks?
1)-- --  We always got along very well.
2) --  We usually got along very well but had some minor arguments.
3) --  I had more than one argument with at least one relative.
4) --  I had many arguments.
5) --  I was constantly involved in arguments.
31. Have you been able to talk about your feelings and problems with at least 
one of your relatives in the last two weeks?
1)-- --  I can always talk about my feelings with one relative.
2) .... I usually can talk about my feelings.
3) --  About half of the time I felt able to talk about my feelings.
4) --  I usually was not able to talk about my feelings.
5) --  I was never able to talk about my feelings.
32. Have you avoided contacts with your relatives during these last two weeks?
1)   I have contacted relatives regularly.
2)   I have contacted a relative at least once.
3)   I have waited for my relatives to contact me.
4)   I avoided my relatives but they contacted me.
5)   I had no contacts with any relatives.
33. Did you depend on your relatives for help, advice, money or friendship during 
the last two weeks?
1)__ __  I never needed to depend on them.
2) __  I usually did not need to depend on them.
3) __  About half the time I needed to depend on them.
4) __  Most of the time I depended on them.
5) __  I depended completely on them.
34. Have you wanted to do the opposite of what your relatives wanted in order to 
make them angry during the last two weeks?
1)__ __  I never wanted to oppose them.
2) __  Once or twice I wanted to oppose them.
3) __  About half the time I wanted to oppose them.
4) __  Most of the time I wanted to oppose them.
5) __  I always opposed them.
35. Have you been worried about things happening to your relatives without reason 
in the past two weeks?
1)
2)
3)
4)
5)
6)
I have not worried without reason.
Once or twice I was worried.
About half the time I was worried.
Most of the time I was worried.
I have worried the entire time.
Not applicable; my relatives are no longer living.
EVERYONE please answer QUESTIONS 36 and 37, even if your relatives are not living,
36. During the last two weeks have you been thinking that you have let any of 
your relatives down or have been unfair to them at any time?
1)
2)
3)
4)
5)
I did not feel that I let them down at all.
I usually did not feel that I had let them down. 
About half the time I felt that I had let them down, 
Most of the time I felt that I let them down.
I always felt that I let them down.
37. During the last two weeks have you been thinking that any of your relatives 
have let you down or have been unfair to you at any time?
1)
2)
3)
4)
5)
I never felt that they let me down.
I felt that they usually did not let me down, 
About half the time I felt they let me down.
I usually felt that they let me down.
I am very bitter that they let me down.
Are you living with your spouse or have been living with a person of the opposite 
sex in a permanent relationship?
1 )
2)
YES. If YES, please answer questions 38 to 46. 
NO. If NO, please go on to question 47.
38. Have you had open arguments with your partner in the last two weeks?
1)
2)
3)
4)
5)
We had no arguments and we got along well.
We usually got along well but had minor arguments. 
We had more than one argument.
We had many arguments.
We were constantly involved in arguments.
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39. Have you been able to talk about your feelings and problems with your 
partner during the last two weeks?
1)-- --  I could always talk freely about my feelings.
2) --  I usually could talk about my feelings.
3) --  About half the time I felt able to talk about my feelings.
4) --  I usually was not able to talk about my feelings.
5) .... I was never able to talk about my feelings.
40. Have you been demanding to have your own way at home during the last two 
weeks?
1)__ __  I have not insisted on always having my own way.
2) --  I usually have not insisted on having my own way.
3) --  About half the time I insisted on having my own way.
4) --  I usually insisted on having my own way.
5) .... I always insisted on having my own way.
41. Have you been bossed around by your partner during these last two weeks?
1) .... Almost never.
2) __  Once in a while.
3) __  About half the time.
4) __  Most of the time.
5) __  Always.
42. How much have you felt dependent on your partner during these last two weeks?
1)   I was independent.
2)   I was usually independent.
3) .... I was somewhat dependent.
4)   I was usually dependent.
5)   I depended on my partner for everything.
43. How have you felt about your partner during these last two weeks?
1)__ __  I always felt affection.
2) __  I usually felt affection.
3) __  About half the time I felt dislike and half the time affection.
4) __  I usually felt dislike.
5) __  I always felt dislike.
44. How many times have you and your partner had sexual intercourse?
1)__ __  More than twice a week.
2) __  One or twice a week.
3) __  Once every 2 weeks.
4) __  Less than once every two weeks but at least once in the last month.
5) __  Not at all in a month or longer.
f
i
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45. Have you had any problems during sexual intercourse, such as pain, during 
these last two weeks?
1)__ __  None.
2) __  Once or twice.
3) __  About half the time.
4) __  Most of the time.
5) __  Always.
6) __  Not applicable, no sexual intercourse took place in the last
two weeks.
46. How have you felt about sexual intercourse during the last two weeks?
1)__ __  I always enjoyed it.
2) __  I usually enjoyed it.
3) __  About half the time I did and about half the time I did not enjoy it.
4) .... I usually did not enjoy it.
5) __  I never enjoyed it.
CHILDREN
Have you had unmarried children, stepchildren or foster children living at home 
during the last two weeks?
1) .... YES. If YES, please answer questions 47 - 50.
2) __  NO. If NO, please go on to question 51.
47. Have you been interested in what your children are doing - school, play or 
hobbies during the last two weeks?
1)__ __  I was always interested and actively involved.
2) __  I usually was interested and involved.
3) __  About half the time interested and half the time not interested.
4) __  I usually was disinterested.
5) __  I was always disinterested.
48. Have you been able to talk and listen to your children during the last two 
weeks? Include only children that are over the age of 2 years.
1)__ __  I always was able to communicate with them.
2) __  I usually was able to communicate with them.
3) __  About half the time I could communicate with them.
4) .... I usually was not able to communicate with them.
5) __  I was completely unable to communicate with them.
6) .... Not applicable; no children over the age of 2 years.
49. How have you been getting along with the children during the last two weeks?
1)   I had no arguments and got along very well.
2)   I usually got along well but had minor arguments.
3)   I had more than one argument.
4)   I had many arguments.
5)   I was constantly involved in arguments.
50. How have you felt towards your children during these last two weeks?
1)__ __  I always felt affection.
2) __  I mostly felt affection.
3) __  About half the time I felt affection.
4) __  Most of the time I did not feel affection.
5) __  I never felt affection towards them.
FAMILY UNIT
Have you every been married, ever lived with a person of the opposite sex or 
ever had children? Please tick the response which is most suited to you.
1) __  YES. If YES, please answer questions 51 to 53.
2) __  NO. If NO, please go on to question 54.
51. Have you worried about your partner or any of your children without any
reason during the last two weeks, even if you are not living together now?
1)__ __  I never worried.
2) __  Once or twice I worried.
3) __  About half the time I worried.
4) __  Most of the time I worried.
5) __  I always worried.
6) __  Not applicable; partner and children are not living.
52. During the last two weeks, have you been thinking that you have let your 
partner or any of your children down at any time?
1) .... I did not feel I let them down at all.
2) __  I usually did not feel that I let them down.
3) __  About half the time I let them down.
4) __  Most of the time I felt that I let them down.
5) __  I let them down completely.
53. During the last two weeks, have you been thinking that your partner or any of 
your children have let you down at any time?
1)__ __  I never felt they let me down.
2)__ __  I felt they usually did not let me down.
3)__ __  About half the time I felt they let me down.
4)__ __  I usually felt they let me down.
5)__ __  I felt bitter that they should have let me down.
FINANCIAL EVERYONE PLEASE ANSWER QUESTION 54.
54. Have you had enough money to take care of your own and your children’s 
financial needs during the last two weeks?
1) ___  I had enough money for needs.
2) .... I usually had enough money with minor problems.
3) .... About half the time I did not have enough money but did not
have to borrow money.
4) .... I usually did not have enough money and had to borrow from others.
5) ___  I had great financial difficulty.
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2 2 4 2 1 6 9 13-14 2 3-5 6 5-7 2
1 1 3 1 4-5 8 12 1 2 5 3-4 1
0
0
0-2 0 0 0-3 0-7 0-11 0 0-1 0^1 0-2 0
SUMMARY
TEST RawScore
Scaled
Score
Information
Comprehension
Arithmetic
Similarities
Digit Span
Vocabulary
Verbal Score
Digit Symbol
Picture Completion
Block Design
Picture Arrangement
Object Assembly
Performance Score
Total Score
VFRBAl SCORF IQ
PERFORMANCF SCQRF IQ
Cl II i s r a i  F SHORE IQ
•Clinicians w ho wish to draw  a “ psychograp lT  on the above table m ay do so by  connecting the subject s raw scores. The m terpren  
however, should take in to  account the reliab ilities o f the subtests and the low er reliab ilities  o f d ifferences between subtest scores.
1. INFORMATION SCORE 1 or 0
SCORE 
1 or 0
SCORE 
1 or 0
1. Flag 11. Height
21. Members of Parliament
2. Ball 12. Italy 22. Genesis
3. Months 13. Clothes
23. Temperature
4. Thermometer 14. Valentine's Day 24. Iliad
5. Rubber 15. Hamlet
25. Blood vessels
6. Prime Ministers 16. Vatican
26. Koran
7. Longfellow 17. New York
27. Faust
8. Weeks 18. Egypt
28. Ethnology
9. Gibraltar 19. Yeast
29. Apocrypha
10. Brazil 20. Population
OBSERVATIONS:
Adapted by permission. Copyright ©  1971,1955 by The Psychoiogical Corporation, New Y o rM lY ^  U S A  ^  ^
All rights reserved, including translation. No part of this w,mout permission in writing from the publishers, and may
The NFER-NELSON Publishing Company Ltd., Darville House, 2 Oxfor oa , 1 1 0 2  05 4
2 (6.85)
2. COMPREHENSION SCORE 
2. 1 or 0
1. Clothes
2. Engine
3. Envelope
4. Bad company
5. Cinema
6. Taxes
7. Iron
8. Child employment
9. Forest
10. Deaf
11. Town land
12. Marriage
13. Still waters
14. Swallow
4. SIMILARITIES SCORE 2, 1 or 0
1. Orange—Banana
2. Coat—Dress
3. Axe—Saw
4. Dog—Lion
5. North-West
6. Eye—Ear
7. Air—Water
8. Table—Chair
9. Egg—Seed
10. Poem—Statue
11. Wood—Alcohol
12. Praise—Punishment
13. Fly—Tree
3. ARITHMETIC SCORE 
2, 1 or 0
6. VOCABULARY
n T— SCORE
1. 15" 0 1
1. Bed
2. 15" 0 1 2. Ship
3. 15"
H I w
0 1 3. Penny
4. 15" 0 1 4. Winter
5. 30" 0 1 5. Repair
6. 30" 0 1 6. Breakfast
7. 30" 0 1 7. Fabric
8. 30" 0 1 8. Slice
9. 30" 0 1 9. Assemble
10. 30" 0 1 10. Conceal
11. 60" 0 1 2 11. Enormous
12. 60" 1 10 0 1 2 12. Hasten
13. 60" 1 11 0 1 2
13. Sentence
14. 120"
1 20 14. Regulate
0 1 2 15. Commence
16. Ponder
17. Cavern
5. DIGIT SPAN SCOR 18. Designate
Digits Forward Circla 19. Domestic
5-8-2
6-9-4
6-4-39
7-2-8-6
4-2-7-3-1 
75-8-3-6
6-1-9-4-7-3
3-9-2-4-87
5-9-1-7-4-2-8
4-1-7-9-3-8-6
5-8-1 -9-2-6-4-7 
3-8-2-95-1-7-4 
2-7-5-8-6-2-5-8-4
7-1-3-9-4-2-5-6-8 _
3
3
20. Consume
4
4
21. Terminate
22. Obstruct
5
5
23. Remorse
6
6
------ 5
24. Sanctuary
25. Matchless
7
7
26. Reluctant
8
8
9
9
Circ(
27. Calamity
28. Fortitude
29. Tranquil
Digits Backward
30. Edifice
2-4
5-8
6-2-9 
4-1-5
3-279
4-9-6-8
1-5-2-8-6
6-1-8-4-3
5-3-9-4-1-8 
72-4-8-5-6 
8-1-2-9-3-6-5 
4-7-3-9-1-2-8 
B4-3-7-6-2-5-8
7-2-8-1-9-6-5-3 __
•• xB
2
2
3
3
31. Compassion
32. Tangible
33. Perimeter
4
4
5
5
6
34. Audacious
35. Ominous
36. Tirade
37. Encumber
7
38. Plagiarize
7 39. Impale
8 ^0. Travesty I
8
F +B
9 8 6 L e 99 V 6 z 8 8 1 L 6 9 8 9 V 6 L 18 Zi
L £ 9 9 1 9 Z L £ 8 ir 6 9 9 V L £ 8 Z 6 1 9 CVI
WECHSLER MEMORY SCALE FORM I
David Wechsler 
Bellevue Hospital, New York
NAME AGE SEX
REFERRED FOR DATE EXAMINER
e L V 8 9 6 1 00 Z L £ 9 V 9 8 Z L 9 e 9 L Z 8 I. PERSONAL AND CURRENT INFO. Score II. ORIENTATION Score
e
o
> V 1 e z 8 e 2 * 1 2 e iz 9 1 00 t?Z L £ \
“ 2. When b o m  . .
3. President of U 
- 4. Before him
4 5. Governor . .
S n d W  6> Mayor
Total
1. Year . . .
2. Month . .
3. Day . . .
4. Where now
5. City in
Total
Score
I. Information
II. Orientation
III. Mental Control
IV. Memory Passages
V. Digits Total ___
VI. Vis. Reprod.
VII. Associate Lng.
Total Raw Score 
Age Correction 
Corrected Score 
MQ (Table 3)
<3)1 OOS 8 L
n III. MENTAL CONTROL (Circle omits; cross out errors.)108HAS 1. (30") 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
11910 2. (30” ) A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
3. (45") 1 4 7 10 13 16 19 22 25 28 31 34 37 40
Time Errors Score Total
Score
8. PICTURE 
COMPLETION
SC O R E
1 or 0
1. Knob
2. Tail
3. Nose
4. Handles
5. Diamond
6. Wafer
7. Nose piece
8. Peg
9. Oar lock
10. Base pins
I 1. Union Jack
12. Dog tracks
13. Cornwall
' |4. Funnels (Stacks)
15. Leg
16. Arm image
17. Finger
18. Shadow
19. Stirrup
20. Snow
21. Eyebrow
9. BLOCK DESIGN
Time SCORE
1. 60"
1
2 0 2 4
2. 60"
1
2 0 2 4
3. 60" 0 | 4
4. 60" 0 4
5. 60" 0 4
6. 60" 0 4
7. 120"
9 1 - 4 0  1 - 1 0
0 4 5 6
8 .  120"
4 4 - 7 0  1 - 4 5
0 4 5 6
9. 120"
4 1 - 4 0  1 - 4 0
0 4 5 6
10. 120"
4 1 - 4 0  > - 4 0
0 4 5 6
10. PICTURE ARRANGEMENT
Order Tim* SCORE
1. Nest 60
1 0 2 4
WXY2
2. House 60
1 0 2 4
f a t2
3. Hold up 60" 0 4
A4 C0
4. Louie 60" 0 4
ATOMIC
5. Enter 60" 0 4
OPENS
6. Flirt 60"
0 2 4
J N A E T  JANET 
A JN ET
7. Fish 120"
2 4 - 4 0  1-2
0 2 4 5 6
EOFMIJ |_____ I F G H I J___ _
EJF6HI
8. Taxi 120"
1 4 - 2 1  • - )
0 2 4 5 6
SALMUC I SAMUEL__
AMUELS
IV. LOGICAL MEMORY
(A) Anna Thompson/ of South/ Boston/ 
employed/ as a scrub woman/ 
in an office building/ reported/ 
at the City Hall/ Station/ 
that she had been held up/ 
on State Street/ the night before/ 
and robbed/ of fifteen dollars/.
She had four/ little children/ the rent/ 
was due/ and they had not eaten/ 
for two days/. The officers/ 
touched by the woman's story/ 
made up a purse/ for her/.
(B) The American/ liner/ New York/ 
struck a mine/ near Liverpool/ 
Monday/evening/. In spite of a blinding/ 
snowstorm/ and darkness/ the sixty/ 
passengers including 18/ women/ 
were all rescued/ though the boats/ 
were tossed about/ like corks/ 
in the heavy sea/. They were brought 
into port/ the next day/ by a British/ 
steamer/.
(A) Number of Memories (B) Number of Memories a c (A+B)Average Score = — =
V. (A) DIGITS FORWARD Score (B) DIGITS BACKWARD Score
L
sea
I I . OBJECT ASSEMBLY
Tim* SCORE
Manikin 120" 0 2 3 4 5
14-20
6
M-1S
7
1-IO
8
Profile 120" 0 2 3 4 5 6 7 8 9
24-4S
I I
24-SS !•» 
12 »]
Hand
o00 0 2 3 4 5 6 7
41-10
9
21-40
10
1-20
I I
Elephant 180" 0 2 3 4 5 6 7 1
21*00
10
21-20
I I
1*20
12
6-ii-3-9 4 Draw a line 2-8-3 3
7-2-8-6 4 through any 4-1-5 3 U
series failed. m
4-2-7-3-1 5 Circle score 3-2-7-9 4 <
7-5-8-3-6 5 for maximum 4-9-6-8 4 0
number repeated to
6-1-9-4-7-3 6 correctly. 1-5-2-8-6 5 in
3-9-2-4-8-7 6 6-1-8-4-3 5 COin
5-9-1-7-4-2-3 7 5-3-9-4-1-8 6
N
in
4— 1-7-9-3-8-6 7 7-2-4-8-5-6 6
in
in
5-8-1-9-2-6-4-7 8 8-1-2-9-3-6-5 7
in
in
3-8-2-9-5-1-7-4 8 4-7-3-9-1-2-8 7 W5
in
Forward Score Backward Score Digits Total
CM
in
tin ted  in U. S. A
Copyright 1945, renewed 1972 by The Psychological Corporation.
All rights reserved. N o  p a rt o f th is reco rd  fo rm  m ay be rep ro d u ce d  in any fo rm  of p rin tin g  o r by any  o th e r m eans, e lec tron ic  o r 
m echan ica l, including, bu t not lim ited  to , pho tocopy ing , aud iov isual reco rd ing  and  tran sm ission , and  p o rtra y a l o r dup lica tio n  in 
any in fo rm atio n  sto rage an d  re trieval system , w ithou t perm ission  in  w riting  from  th e  pub lisher. See C a ta lo g  fo r fu rth e r in fo rm atio n .
T he Psychological C o rp o ra tio n , N ew  Y ork , N . Y . 10017
72 245AS 9 987306
t-v- ■] 
VI-A VI-B
VI C-l. C-2
Fold Part VII under on broken line before giving paper to subject for drawing
VI.
VII.
VISUAL REPRODUCTION C-l Total
ASSOCIATE
LEARNING First Presentation
First Recall Easy Hard
North ____
Fruit ____
Obey
Rose ____
Baby ____
Up
Cabbage ____
Metal ____
School ____
Crush ____
TOTAL
Second Presentation
Metal - Iron Rose - Flower
Baby - Cries Obey - Inch
Crush - Dark North - South
North - South Cabbage - Pen
School - Grocery Up - Down
Rose - Flower Fruit - Apple
Up - Down School - Grocery
Obey - Inch Metal - Iron
Fruit - Apple Crush - Dark
Cabbage - Pen Baby - Cries
Second Recall Easy Hard
Cabbage
Baby
Metal
School
Up __
Rose
Obey
Fruit ____
Crush
North ____
TOTAL
Third Presentation
Baby
Obey
North
School
Rose
Cabbage
Up
Fruit
Crush
Metal
Cries
Inch
South
Grocery
Flower
Pen
Down
Apple
Dark
Iron
Third Recall Easy Hard
Obey
Fruit
Baby
Metal
Crush
School
Rose
North
Cabbage
Up ____
TOTAL
in Part
Easy 1) 
2 ) '  
3)!
(A)Total' 
A -s- 2 ‘
Hard 1) 
2 ) "  
3)'
(B)Total"
SCORE
WECHSLER MEMORY SCALE FORM II
Calvin P. Stone 
itanford University, California
Name
I. PERSONAL AND CURRENT
INFORMATION Score
1. A ge ........................................................... ..........
2. When b o r n .............................................
3. P resident of the U.S.............................
4. Before h im  ..........................................
5. G o ve rn o r................................................ ..........
6. M a y o r .....................................................  ..........
Score
David Wechsler 
Bellevue Hospital, New York
Age_____________ Sex___________Date_______________
R eferred fo r____________
Tota l Raw S co re ..............
Score C orrection  fo r  Age
Corrected S co re ..............
MQ(Table 3 )......................
Examined by:
NOTES:
n . ORIENTATION
1* Year
2# Month
3 a Day a a a a a a a a a a a a a a
4. Where n o w ..........................
5. C ity  in ............................... ..
Score
m. M ENTAL CONTROL T im e E rro rs  Score
1. Alphabet (30” )
2. 20 to 1 (30” )  --------  ---------
3. Counting by 4 s (45” ) ____________ _______
(1 -5-9  up to 53)
Score ..............
IV. (A) Dogs/are tra ined /to  fincL/the wounded/in 
w ar t im e ./  Police dogs/are also tra in e d / 
to rescue/drowning people ./ Instead of 
running/down to the water/and s tr ik in g  ou t,/ 
1 they are taught/to m ake/a fly ing  leap ,7 by 
which they save/many swim ming s trokes / 
and valuable/seconds of t im e ./  The E u ro ­
pean sheep dog/makes the b e s t/p o lice / 
dog./
Number of M e m o rie s_____
(B) M any /schoo l/ch ild ren /in  n o rthe rn /F ran ce / 
were k il le d /o r  fa ta lly  h u r t , /  and o thers / 
se rious ly  in jured/w hen a she ll/w recked / 
the schoolhouse/in th e ir  v illa g e ./ The 
ch ild ren /w ere  thrown/down a h ills ide /an d  
across /a  rav ine /a  long d is tance/from  the 
schoolhouse./ Only two/children/escaped 
un in ju red ./
Number of M em ories
Average Score = (A+B) =
V« (A) DIGITS FORWARD Tota l D ig its  Score.
4) 2 8 6 1 
5 3 9 4 --
5) 7 4 2 9 6
8 5 1 6  4
6) 8 4 2 7 5 1 
7 2 9 5 3 6 --
7) 7 4 8 2 5 9 1
8 3 9 6 1 5  2
8) 2 6 9 5 8 3 7 1  
3 7 2 9 4 1 5 8 --
9)* (5 9 4 8 2 7 3 1  
(4 2 9 3 8 6 1 7
10)*(5 2 7 1 8 4 9 3 6  2) 
(4 9 7 3 6 1 5 8 4  7) -- Scor
(B) DIGITS BACKWARD
3) 7 5 1 
2 9 6 -- 4)
3 5 8 2 
9 6 1 7
5) 4 7 1 8  6 
3 9 2 6 1 -- 6) 6 3 9 1 5  8 4 8 1 6  3 7
7) 5 4 9 2 7 3 6  
2 5 1 9  4 7 3 --
8)*j12 7 1 5 3 9 6 4) 
[3 8 5 9 4 7 1 6)
9)*(9 1 6 4 8 3 7 5 2)
(5 2 7 1 8 4 9 3  6) ~
Score
♦Not counted in  score i f  used.
V I. VISUAL REPRODUCTION 
1 2 3 -L  3-R
Score
tod In U. S. A.
Copyright 1948
The Psychological Corporation, 522 Fifth Avenue, New York 18, N. Y.
48-102 AS
CM
PGI
CO
1-3I
CO
H
>
H
>
Fold Part VII under before giving paper to subject for drawing in Part VI.
vn. ASSOCIATE LEARNING
First Presentation
Come - Go 
Lead - Pencil 
In - Although 
Country - France 
Dig - Guilty 
Lock - Door 
Jury - Eagle 
Murder - Crime 
Knife - Sharp 
Necktie - Cracker
Second Presentation
Knife - Sharp 
Jury - Eagle 
Country - France 
Lead - Pencil 
Necktie - Cracker 
Murder - Crime 
Lock - Door 
Come - Go 
Dig - Guilty 
In - Although
First Recall Easy Hard Second Recall Easy Hard Third Recall
Knife
Lead
Jury
Country
In
Murder
Necktie
Lock
Come
Dig
Total
Lock
Dig
Come
J^y
Knife
Country
In
Murder
Necktie
Lead
Total
Lead
Lock
Necktie
Come
Dig
Country
Jury
Knife
In
Murder
Total
Third Presentation
Country - France 
Necktie - Cracker 
Murder - Crime 
Dig - Guilty 
Come - Go 
In - Although 
Lock - Door 
Jury - Eagle 
Lead - Pencil 
Knife - Sharp
Easy Hard Easy 1)
  2
  3)
  (A)Ibtal
  A 7 2
Hard 1
(B) Tbtal
SCORE
COMPLEX FIGURE TEST II
